



PWYLLGOR ADNODDAU CYNALIADWY SUSTAINABLE RESOURCES COMMITTEE

DYDDIAD Y CYFARFOD: DATE OF MEETING:	10 November 2022
TEITL YR ADRODDIAD: TITLE OF REPORT:	Finance Report and Forecast Month 6 2022/23
CYFARWYDDWR ARWEINIOL: LEAD DIRECTOR:	Huw Thomas, Director of Finance
SWYDDOG ADRODD: REPORTING OFFICER:	Rebecca Hayes, Senior Finance Business Partner

Pwrpas yr Adroddiad (dewiswch fel yn addas)

Purpose of the Report (select as appropriate)

Ar Gyfer Trafodaeth/For Discussion

ADRODDIAD SCAA SBAR REPORT

Sefyllfa / Situation

The purpose of the report, attached at Appendix 1, is to outline Hywel Dda University Health Board's (HDdUHB) financial position to the end of the financial year 2022/23 against the Annual Plan.

The Committee is asked to note the detail included within Appendices 1a and 2, which provides the full commentary and tables submitted to Welsh Government (WG) as part of our reporting requirements. The monthly reporting to WG is in line with the written report provided to the Sustainable Resources Committee and Board.

Cefndir / Background

The Health Board's revised draft Financial Plan is to deliver a deficit of £62.0m, after savings of £13.9m; this recognises the inadequate level of assurance around directorate overspend mitigation plans and the identification of a further £15.5m of savings schemes deliverable within the current financial year against our initial £25.0m deficit Plan.

Month 6 position:

- The Month 6 Health Board financial position is an overspend of £6.0m, which is made up of £43.9m operational variance and an original deficit plan of £2.1m; this is after recognising £0.3m of assumed WG transitional funding for COVID-19 and £1.3m for Exceptional Energy costs. £1.5m of savings schemes were delivered in line with identified plans.
- Of the £3.9m overspend in-month, £1.0m relates to undelivered savings plans against the original target and £2.9m relates to operational pressures. These pressures are mainly being experienced within our Unscheduled Care teams, but also within Medicines Management in relation to Primary Care Prescribing.

- The Health Board has received confirmation of WG funding to match the costs of the COVID-19 programmes (Tracing, Testing, Mass Vaccinations and PPE), and has received initial guidance from WG to assume that funding will be provided to offset the transitional costs of COVID-19 of £6.7m and the Exceptional Energy, Health and Social Care Levy and Real Living Wage commissioned services costs of £12.3m.

End of Year Forecast

- Since our initial plan submission, each Executive Director and their respective leadership teams have been reviewing their operational plans to deliver a step change through a Target Operating Model (TOM) approach; the basis for our transformation improvement programmes, supported by our Planning Objective structure and governance. Whilst these have yielded benefits, such as our recovery plan to deliver dedicated ring-fenced wards for elective procedures, they are unfortunately not sufficient to improve the financial outlook. The Health Board continues to have to commit expenditure at a consistent rate to maintain services whilst experiencing significant system demand and challenges.
- Of the identified savings schemes of £13.9m, only a small number are currently assessed as recurrent, with a full year effect of £2.0m. This is contributing to the deterioration in the underlying deficit to £75.0m from the brought forward 2021/22 position of £68.9m, which presents a challenge to be addressed as part of our TOM.
- Following feedback from WG regarding the revised draft Financial Plan, the Board has further challenged teams to urgently identify management actions to reduce the organisation's expenditure trajectory, on an in-year basis as a minimum.

Asesiad / Assessment

The Health Board's key targets are as follows:

- Revenue: to contain the overspend within the Health Board's planned deficit
- Savings: to deliver savings plans to enable the revenue budget to be achieved
- Capital: to contain expenditure within the agreed limit
- PSPP: to pay 95% of Non-NHS invoices within 30 days of receipt of a valid invoice
- Cash: While there is no prescribed limit for cash held at the end of the month, WG encourages this to be minimised and a rule of thumb of 5% of monthly expenditure is used. For the Health Board, this is broadly £4.0m.

Key target		Annual limit	YTD limit	Actual delivery	Forecast Risk
Revenue	£'m	62.0	28.1	28.9	Low*
Savings	£'m	13.9	6.8	6.8	Low**
Capital	£'m	31.1	8.2	8.2	Low
Non-NHS PSPP	%	95.0	95.0	94.9	Low***
Period end cash	£'m	4.0	4.0	6.4	High****

* The Health Board is forecasting a financial outturn position of £62.0m in line with the re-submitted draft annual plan, which is £37.0m higher than the previous planned deficit of £25.0m. Whilst the delivery risk to the revised deficit of £62.0m is considered to be Low, this is an unacceptable level of deficit and urgent management actions are required to address the underlying position. There is a significant risk that the revised deficit plan may not be accepted by WG. The re-submitted Plan has been phased in line with the Months 1-3 Actual results and the Month 3 forecast. This decision was taken to prevent reporting to the organisation a YTD

or in-month “underspend” against a flat profile of the £62.0m draft deficit as this was considered a misleading message.

** Whilst the delivery of planned savings schemes are on track, the revised annual limit is £15.5m lower than the original plan due to an inadequate level of assurance around the identification of deliverable savings schemes; this lower level of savings has contributed to the increase in the planned deficit of £62.0m. Furthermore, of the identified savings schemes of £13.9m, only a small number are currently assessed as recurrent, with a full year effect of £2.0m. This is contributing to the deterioration in the underlying deficit to £75.0m from the brought forward 2021/22 position of £68.9m, which presents a challenge to be addressed as part of our TOM.

***The Health Board did not achieve its PSPP target of paying 95% of its non-NHS invoices within 30 days in Quarter 2 (93.6%), which has adversely affected the cumulative position (94.9%). This was caused by delays in authorising invoices by the service; a process has been implemented to assist accounts payable to obtain the authorisation in a timely manner.

*** If WG do not fund the cash consequences of the revenue deficit, there is a significant risk to the period end cash position. A Financial Cashflow Management Strategy has been developed to proposed mitigation plans to ensure the Health Board can make its critical payments on time.

Inefficiency activity drivers

As the outcome of work surrounding the allocation of resources, based on our population health needs compared to national benchmarks, inefficiency activity drivers are articulated with financial quantification.

The strategic activity drivers that are having an adverse impact on our financial deficit are split into the three macro elements; Demand, Supply and Configuration, and Efficiency. The organisation has work programmes, led by Executive Directors, to implement improvement activities for each specific micro driver articulated.

Unscheduled Care Configuration broadly relates to the number of hospital sites and front doors the Health Board currently manages, which is linked to our long-term strategy, so will not have a financial improvement in the short-term.

Directorate		Demand	Supply			Configuration & Efficiency				Totals
		Ready to leave patients	Agency premium: Medical	Agency premium: Nursing	CHC (s117)	Medically fit patients	Multiple site (A&E & Inpatient)	Multiple site (OP)	Multiple site (Planned Care)	
Unscheduled Care Configuration							16.6	0.8		17.4
Carmarthenshire County		4.0		0.1						4.1
Ceredigion County		2.9								2.9
Pembrokeshire County		3.7		0.2						3.9
Unscheduled Care Bronglais			0.5	0.2		1.8				2.4
Unscheduled Care Glangwili			0.3	2.1		4.3				6.7
Unscheduled Care Prince Philip			0.3	1.2		3.9				5.4
Unscheduled Care Withybush			0.4	1.9		5.6				7.9
Women & Children			0.5	0.2						0.8
Planned Care			1.2	0.8				0.7	1.1	3.7
Mental Health & Learning Disabilities	Carms Pembs Cered		0.3	0.9						1.2
					4.9					4.9
					2.2					2.2
					2.9					2.9
Diagnostics									2.0	2.0
		10.6	3.4	7.5	10.0	15.5	16.6	1.5	3.1	
		10.6			21.0				36.7	68.3

Argymhelliad / Recommendation

The Sustainable Resources Committee is asked to note and discuss the financial position as at Month 6.

Amcanion: (rhaid cwblhau)

Objectives: (must be completed)

Committee ToR Reference: Cyfeirnod Cylch Gorchwyl y Pwyllgor:	4.5 Provide assurance on financial performance and delivery against Health Board financial plans and objectives and, on financial control, giving early warning on potential performance issues and making recommendations for action to continuously improve the financial position of the organisation, focusing in detail on specific issues where financial performance is showing deterioration or there are areas of concern.
Cyfeirnod Cofrestr Risg Datix a Sgôr Cyfredol: Datix Risk Register Reference and Score:	1432 (score 25) Delivery of the Health Board's draft interim Financial Plan for 2022/23. 1199 (score 25) Achieving financial sustainability.

Safon(au) Gofal ac Iechyd: Health and Care Standard(s):	5. Timely Care 7. Staff and Resources
Amcanion Strategol y BIP: UHB Strategic Objectives:	All Strategic Objectives are applicable
Amcanion Cynllunio Planning Objectives	All Planning Objectives Apply
Amcanion Llesiant BIP: UHB Well-being Objectives: Hyperlink to HDdUHB Well-being Objectives Annual Report 2018-2019	9. All HDdUHB Well-being Objectives apply

Gwybodaeth Ychwanegol: Further Information:	
Ar sail tystiolaeth: Evidence Base:	Monitoring returns to Welsh Government based on HDdUHB's financial reporting system.
Rhestr Termau: Glossary of Terms:	Contained within the report
Partïon / Pwyllgorau â ymgynhorwyd ymlaen llaw y Pwyllgor Adnoddau Cynaliadwy: Parties / Committees consulted prior to Sustainable Resources Committee:	Finance Team Management Team Executive Team

Effaith: (rhaid cwblhau) Impact: (must be completed)	
Ariannol / Gwerth am Arian: Financial / Service:	Financial implications are inherent within the report.
Ansawdd / Gofal Claf: Quality / Patient Care:	The impact on patient care is assessed within the savings schemes.
Gweithlu: Workforce:	The report considers the financial implications of our workforce.
Risg: Risk:	Financial risks are detailed in the report.
Cyfreithiol: Legal:	HDdUHB has a legal duty to deliver a breakeven financial position over a rolling three-year basis and an administrative requirement to operate within its budget within any given financial year.

Enw Da: Reputational:	Adverse variance against HDdUHB's financial plan will affect its reputation with Welsh Government, Audit Wales, and with external stakeholders.
Gyfrinachedd: Privacy:	Not applicable.
Cydraddoldeb: Equality:	Not applicable.

Hywel Dda UHB

Month 6 YTD Financial Performance and EoY Forecast

Sustainable Resources Committee

10th November 2022

Month 6 Executive Summary

The Health Board's revised draft Financial Plan is to deliver a deficit of £62.0m, after savings of £13.9m; this recognises the inadequate level of assurance around the identification of a further £15.5m of savings schemes deliverable within the current financial year against our initial £25.0m deficit Plan. The further deterioration of £21.5m recognises the fruition of the operational variation risk and a transfer into the Core position of COVID-19 responses that were initially planned to be decommissioned, but have been deemed necessary to continue.

Financial position	Month 5 £'m	Month 6 £'m	YTD £'m	EOY £'m
Original Planned deficit	2.1	2.1	12.5	25.0
Undelivered Savings plans	1.7	1.0	7.9	15.5
Operational variance (including transfers from COVID-19)	2.5	2.9	8.5	21.5
COVID-19 expenditure	1.2	1.6	12.9	24.6
Operational variance before WG COVID-19 funding	7.5	7.6	41.8	86.6
WG COVID-19 funding: 'Programme' costs	(0.9)	(1.1)	(7.4)	(14.8)
WG COVID-19 funding: 'Other' costs	(0.1)	(0.2)	(0.8)	(3.1)
WG COVID-19 funding: 'Transitional' costs	(0.2)	(0.3)	(4.7)	(6.7)
Reported financial position	6.3	6.0	28.9	62.0

- Financial pressures continue across the Health Board with particular pressures on pay, where the Health Board continue to rely on Agency staff to support high levels of vacancies and in Medicines Management where a combination of prescription growth and the price of Cat M and NCSO drugs are adversely affecting run rates.
- Following feedback from WG regarding the revised draft Financial Plan, the Board has further challenged teams to urgently identify management actions to reduce the organisation's expenditure trajectory, on an in-year basis as a minimum.
- Opportunity movements remains a concern however Finance Business Partnering teams are facilitating Executive led reviews of the Opportunities Framework, which will update the status of schemes in the coming weeks.

Month 6 In-Month 2022/23: Key drivers (£'m)



The value of £0.3m is assumed as a Transitional funding allocation to match non-programme transitional COVID-19 costs incurred. £1.3m of funding has been assumed to match Exceptional Energy costs. Exceptional CHC inflationary costs were incurred as a YTD charge in-month, however the split between Core and Exceptional is to be confirmed. Both funding streams are assumed but not confirmed and therefore poses a risk to the result.

Programme funding relates to the following in response to COVID-19 match-funded by WG:

- TTP
- COVID-19 mass vaccination programme
- PPE

£1.0m was released to match costs in Month 6.

Operational variance excluding unidentified savings is £2.9m; underspends in non-USC not materialising to offset £2.1m of non-COVID-19 overspend.

Month 6 In-Month 2022/23: Key drivers (£'m)

Directorate	Non COVID-19	COVID-19	Total	Non-COVID-19: Operational Driver comments COVID-19: list scheme(s) and value
Undelivered Savings	1.0	0.0	1.0	Non COVID-19: Undelivered planned savings across the Health Board.
Medicines Management	0.7	0.0	0.7	Non COVID-19: £672 over spent. £768k PARS over spend due to baseline price increases May actuals and volume growth in May & June actuals. -£201k monthly variance on drug rebates based on FY22 values. Remainder of overspend due to enabling works in WGH and drugs costs.
USC GGH	0.7	0.0	0.7	Non COVID-19: Site on red for 30 days, 23 surge beds and increasing high levels medically fit of 71. Pay £474k - Nursing £224k with increased agency costs in particular A&E and Teifi, HCSW £77k over due to 29 wte over established mainly within A & E and Ceri Ward (inc Bank usage), Medical Staff £156k over due to Locum usage in General Medicine & a high cost Medacs Consultant in A&E covering vacancies * Non Pay £190k overspent- Mainly drugs £73k over, Clinical Services £22k, unfunded SLA's £20k and SDEC Rent costs of £10k
USC WGH	0.5	0.1	0.6	Non COVID-19: With 195 funded beds, we see site pressures of 84 medically optimised patients with 48 on discharge pathways, an average of 41 surge beds (up from 40 in M5) and an average of 20 patients in A&E needing a bed (21 in M5). As a result, nursing/HCSW is £215k overspent and medical & dental is £104k overspent due to locum spend. Non pay has a drug/clinical supplies overspend of £106k driven by high cost gastro drugs. Additionally, non pay has seen one off spends totalling £30k on various cabinets, equipment and maintenance contracts. COVID-19: Primarily driven by Puffin Ward pay costs of £95k including bank and agency of £51k. Spend should decrease month on month as use of Puffin decreases with substantive staff in the process of being moved to other wards.

Month 6 In-Month 2022/23: Key drivers (£'m)


Directorate	Non COVID-19	COVID-19	Total	Non-COVID-19: Operational Driver comments COVID-19: list scheme(s) and value
USC PPH	0.5	0.0	0.5	Non COVID-19: Increased pressure on site with Red Days at 21, with increasing numbers of medically fit at 7. Pay £256k overspent - Nursing £100k over(additional 171 shifts booked in comparison of M5), HCSW 14 wte over established across several wards including MIU and AMAU (inc Bank usage), Medical Staff £58k over due to continued locum usage in Gen Med, historical unfunded Consultant post and additional SDEC costs. Non Pay £281k overspent - due to insulin pumps & consumables £123k & drugs £139k
USC BGH	0.4	0.0	0.4	Non COVID-19: Continued pressure in September. Average 8 unplaced in ED. Increased use of off-contract nurse agency in the month. Covid outbreak on Site reported in Sept with total of 15 beds across the Site closed from mid month impacting elective surgical activity. Increased sickness in nursing and medical plus agency to fill vacancy gaps resulting in increased variable pay costs incurred in the month of £355k; Non Pay clinical supplies including drug cost pressure of £52k in September reflecting continued surge activity.
Mental Health	0.4	0.0	0.4	Non COVID-19: Income (£102.7K) this is due to £97 K request for Partnership funding to cover Buvidal Drug Costs for April-August 22. SMAFF Funding. Pay (47K) - High levels of vacancies totalling (£445K) offset by £397k variable pay. (Bank £251K and Agency £52K and £91K locum costs). Main vacancies within Nursing (£270k) off set £47k agency and £85k bank to cover sickness and vacancies, Medical (£56k) offset by £91k locum costs. Non Pay £ 540K , CHC £389 £(67K Growth/Inflationary)£28K Furniture Grivelle Court,£32K Training course .£30K Accrual .
LTAs	(0.5)	0.0	(0.5)	Non COVID-19: Majority of variance to budget is as a result of WHSSC being under budget (£370K) and C&V LTA being (£154K) under budget based on under performance performance on LTA. SBU is £74K over budget due to an increase in Blood Products for September.

Month 6 In-Month 2022/23: Deviation from prior forecast (£'m)



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Hywel Dda
University Health Board



Month 6 In-Month 2022/23: Deviation from prior forecast (£'m)



GIG
CYMRU
NHS
WALES


Bwrdd Iechyd Prifysgol
Hywel Dda
University Health Board

Directorate	Non COVID-19	COVID-19	Total	Non-COVID-19: Operational Driver comments COVID-19: list scheme(s) and value
Mental Health	0.3	0.0	0.3	Non COVID-19: Income (£98K) this is due to £97K request for Partnership Funding to cover Buvidal Drug costs for April - August 22. SMAFF Funding. Pay £250K, £65K New Medical Doctors and Locum Consultants costs, 28 K new students £95K Bank and £52 K agency to cover sickness and vacancies, £20K, 2.5 wte New B3 Admin staff . Non Pay £193K, £67K CHC Growth Costs,£30K Training Courses MHL D Mgt and Psychotherapy , £28K new Furniture Grivelle Court, £19K Rent + Rates costs Grivelle and LPMHSS Ceredigion and 6 K electrical works Brynmair Clinic.
USC GGH	0.2	0.0	0.2	Non COVID-19: Deterioration of £207k. Pay £150k -Nursing £37k due to increasing number of shifts booked, Medical Staff £96k due to increased support in relation to Junior Doctor change over and newly appointed high cost agency in A& E covering consultant vacancy. Non Pay £66k worsening - Drugs reduction in month was offset by increased costs against Clinical Services and supplies(Pacemakers) & Establishment Costs
USC BGH	0.2	0.0	0.2	Non COVID-19: Deviation to Forecast of £174k. Mainly within Pay £136k - Nursing main cost driver (£78k) with continued site pressures and increased sickness resulting in off contract usage in addition to partnership nurses covering more gaps; Medical Pay deviation of £40k driven by additional support for new drs to cover prescribing and on call commitments plus increased sickness due to covid outbreak. Non Pay within Drugs and Establishment Expenses for removal expenses.
Planned Care	0.2	0.0	0.2	Non COVID-19: Planned Care is £156k worse than forecast. Pay is £95k worse due to higher than anticipated nurse agency spend within Critical Care, relating to increased occupancy of 3.5% at GGH (90.6% v 87.1%) on the units with 733 additional nurse agency hours. Non pay is £49k worse than forecast. This largely due to an increase in Gynae procedures using higher cost consumables.

Month 6 In-Month 2022/23: Deviation from prior forecast (£'m)

Directorate	Non COVID-19	COVID-19	Total	Non-COVID-19: Operational Driver comments COVID-19: list scheme(s) and value
FY23 Savings	(0.3)	0.0	(0.3)	Non COVID-19: Recognition of YTD VAT recovery on digital SLA
LTAs	(0.3)	0.0	(0.3)	Non COVID-19: Deviation to forecast as a result of £254K reduction in WHSSC based on YTD Risk Share. C&V reduction of £162K, HCD and Orthopaedic underperformance and an increase in SBU. SBU increase mainly as a result of an in month increase in Blood Products.
Pathology	(0.2)	0.0	(0.2)	Non COVID-19: Ibrutinib drug rebate for prior years confirmed in month following pharmacist review. Previously classed as possible opportunity £200k, but now realised and brought in to M6 position.

Month 6 EoY 2022/23: Key drivers (£'m)



- The value of £6.7m is assumed as a Transitional funding allocation to match non-programme transitional COVID-19 costs incurred; this funding is assumed but not confirmed and therefore poses a risk to the result.
- Exceptional cost of Utilities assumed to be fully funded on a match basis to the value of £15.8m.

Month 6 EoY 2022/23: Key drivers (£'m)

Directorate	Non COVID-19	COVID-19	Total	Non-COVID-19: Operational Driver comments COVID-19: list scheme(s) and value
Undelivered Savings	15.5	0.0	15.5	Non COVID-19: Undelivered planned savings across the Health Board.
WGH	4.5	1.2	5.7	<p>Non COVID-19: A&E pressures leading to increased non funded additional shifts with new A&E bank rates introduced in M6. Ward pressures from medical admissions and discharge challenges driving surge beds alongside recruitment challenges resulting in premium agency and bank costs pressures. Continued use of locums to fill vacancies, cover non prescribing doctors and those unable to cover on call shifts. Non pay pressures tend to be related to high cost gastro drugs.</p> <p>COVID-19: Continued use of Puffin Ward. The ward is mainly staffed using bank and agency with limited substantive roles.</p>
GGH	5.0	0.0	5.0	<p>Non COVID-19: Continuation of site pressures, especially on A&E with high levels of Nursing vacancies and use of surge beds are driving Nursing & HCSW cost pressures of £1.86m. Vacancies and Locum cover attribute to Medical & Dental overspends of £1.1m. Drugs overspend of £998k due to acuity and frailty of patients. Other Non Pay of £1m is to due unfunded Pacemakers, SLAs with BRC, SDEC rent and £113k of previous years undelivered savings.</p>
PPH	4.3	0.5	4.8	<p>Non COVID-19: Continuation of site pressures and high levels of vacancies are driving Nursing and HCSW cost pressures of £865k. M&D £591k overspend, due to the historical funding shortfall against Consultants and increased locum costs covering sickness and vacancies</p> <p>*Previous Savings targets of £432k (bed closures not materialising). Non Pay overspends of £2.4m include £1.4m of Clinical Services and Supplies driven by high costs of insulin pumps and consumables (mainly due to increased activities) and Drug overspends of £872k.</p> <p>COVID-19: COVID forecast driven by Pay £0.268m and Non Pay £0.258m. Pay mainly driven by Additional Clinical Services £0.090m, & Nursing & Midwifery £0.125m. Included in figures costs relate to the Acute Surge Capacity £0.108m against RN's and HCSW's. Non Pay overspend driven by Homecare drugs costs £0.258m.</p>

Month 6 EoY 2022/23: Key drivers (£'m)


Directorate	Non COVID-19	COVID-19	Total	Non-COVID-19: Operational Driver comments COVID-19: list scheme(s) and value
Medicines Management	3.6	0.2	3.8	Non COVID-19: Overspend relates to Primary Care Prescribing with PARS projected overspend of +£4.6m driven by items growth and price inflation for Baseline drugs rising for July and the significant increase in costs for NCSO drugs+£360k forecast overspend on WP10's driven by prescribing in Oncology during the first half of the year and -£1.4m forecast overachievement on rebates based on average rebates seen on FY22 COVID-19: Q1 prescribing costs attributed to regime changes resulting from Covid
Facilities	1.7	1.7	3.4	Non COVID-19: Income - expectation is (£501k) in excess of target for year due to BG rebates; Pay - expected overspend of £845k due to increased variable pay above budget mainly in 1st quarter due to double running from transfer of staff £470k, transfer of portering posts moved from COVID £250k, plus unfunded apprenticeships; Non pay - expectation is an overspend of £1.33m based on utilities costs (unfunded) £650k, postage £450k, increased waste and provision increases. There were also some one off spends in M1 & M2. COVID-19: £1.28m worth of costs in regards to the enhanced cleaning programme; £223k of various remediation costs, including 1 wte maintenance engineer; £232k worth of pay costs for staffing in relation to service requests in Q1, now part of core, including additional porters.
BGH	3.3	0.1	3.4	Non COVID-19: The EoY Forecast is driven by Pay pressures of £2.7m and Non Pay of £0.6m; the Pay position reflects the continued demand for beds and the surge into all beds / chairs / trolleys (currently running at 8 patients waiting for a bed in ED) and an increased in the high level of sickness and vacancies seen in Nursing and Medical. Increased shifts incurred with off contract agencies in September and additional cover provided by medical for new Drs changeover. Drug costs and activity with increasing level of complex patients being admitted. COVID-19: Covid related costs for Red and Green pathways
Reserves	(4.3)	0.8	(3.5)	Non COVID-19: Central release of reserves £(3.1)m, Central COVID-19 sickness and Drug adjustment £(0.5)m, pay enhancement for overtime £(0.7)m COVID-19: Central COVID-19 sickness and Drug adjustment £0.5m, pay enhancement for overtime £0.3m

Month 6 EoY 2022/23: Deviation from prior forecast (£'m)



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Hywel Dda
University Health Board



Note: Within the £(2.9)m reported as other directorate movements, £(2.5)m relates to the in month movement in risk mitigation.

Month 6 EoY 2022/23: Deviation from prior forecast (£'m)

Directorate	Non COVID-19	COVID-19	Total	Non-COVID-19: Operational Driver comments COVID-19: list scheme(s) and value
MH & LD	1.0	0.0	1.0	Non COVID-19: Income (158K) Income from Buvidal Drugs WG Funded Pay 892K New Doctors , One consultant and 2.3wte Speciality Doctors £145K, 2.5 wte New B3 Admin staff 80K, New nurses 72K, Bank and Agency £570K to cover continued vacancies and sickness. Non Pay £291K , CHC Growth Costs 221K (6 new , 2 ended and 10 emended packages, Drugs 32K, Clinical Supplies 31K (price increases).
Medicines Management	0.8	0.0	0.8	Non COVID-19: The main driver for the deviation is due to the increased cost of NCSO drugs. The monthly cost has continued to rise due to the rising prices and some high quantity drugs moving onto the concessions list with the August number of items being the highest ever seen. Alendronic Acid is a particularly significant driver this year. July-Sept has therefore been adjusted by £500k to reflect the increase in items and cost. The July Category M price per unit has increased by 7p which has moved the forecast by £200k.
Planned Care	0.5	0.00	0.5	Non COVID-19: The forecast has worsened by £0.461k. This reflects the in-month deviation of £156k of which £95k related to higher than anticipated agency spend in critical care together with higher non pay theatre spend of £49k. Recent decisions made around undertaking additional internal waiting lists (Circa £225k) and continuation of medinet clinics from October onwards (£120k) in order to achieve ministerial targets have increased the forecast by £345k. This is offset by small movements across a number of areas of £40k.
WGH	0.4	0.0	0.4	Non COVID-19: A worsening site operational position has been driven by a reduced number of discharges which has impacted increased surge beds and patients sat in A&E needing a bed above forecast. This has resulted in the largest number of medically optimised patients on site. These pressures have impacted increased bank and nurse agency usage and non pay clinical supplies and drugs.

Month 6 EoY 2022/23: Deviation from prior forecast (£'m)

Directorate	Non COVID-19	COVID-19	Total	Non-COVID-19: Operational Driver comments COVID-19: list scheme(s) and value
BGH	0.4	0.0	0.4	Non COVID-19: The deviation to Forecast reflects the pressures reported in M6 for surge capacity utilising off contract nurse agencies, increased sickness due to Covid and additional support for new Drs changeover since August, with retrospective claims received in September, which results in Pay EoY deviation to Forecast of £281k; Non Pay reported pressures in M6 in connection with increased drug cost pressures, forecast to year-end, due to patients presenting later in their care pathway (£77k).
Carmarthenshire County	0.3	0.0	0.3	Non COVID-19: A £257k worsening in forecast. Pay £109k deterioration - due to RIF plans being finalised with the County position and Non Pay £124k - driven by a £165k deterioration in CHC forecast which is client driven (30 new, 21 ended).
Savings delivery	(0.5)	0.0	(0.5)	Non COVID-19: Recognition of new scheme in relation to VAT recovery on digital SLA.

Month 6 EoY 2022/23: Risks

Risks	£'m	RAG
Primary Care: Cluster c/f underspend	0.5	HL
GGH: opening Preseli Ward	0.2	HL
Pathology: PHW respiratory panel testing	0.2	HL
Carms County: Joint Equipment Stores	0.2	HL
Other < £0.2m	0.4	HL
Total highly likely	1.5	
Meds Mgt: 3% volume item growth	1.5	P
Meds Mgt: NCSSO item increase	1.2	P
Planning: VBHC expenditure (£1.9m balance)	0.9	P
MHLD: underspend request plans	0.8	P
MHLD: Recruitment into WG schemes	0.6	P
Primary Care: Social Prescribing etc	0.5	P
Meds Mgt: Drug rebate uncertainty	0.5	P
Oncology SACT drug costs up 5%	0.4	P
Therapies: recruitment students	0.3	P
Carms County: RIF plan vacancy recruitment	0.3	P

Risks	£'m	RAG
Planned Care: Earlier increased activity	0.3	P
Planned Care: Recruitment demountable WTEs	0.3	P
Planned Care: Critical Care Winter/COVID	0.3	P
Meds Mgt: WP10s re homecare	0.3	P
WGH: PACU recruitment	0.2	P
Planning: PBC Cat 1 recruitment	0.2	P
Other <£0.2m	1.6	P
Total possible	10.2	
Total Risks	11.7	

Month 6 EoY 2022/23: Opportunities

Opportunities	£'m	RAG
Other <£0.2m	(0.1)	HL
Total highly likely	(0.1)	
MHLD: WG funding ASD/CBT waiting lists	(0.8)	P
MHLD: WG funding if evidence recruitment	(0.7)	P
Meds Mgt: Drug rebate uncertainty	(0.5)	P
Digital: WAST funding received	(0.2)	P
Planning: PBC Cat 1 posts funded	(0.2)	P
Other <£0.2m	0.0	P
Total possible	(2.4)	P
Total Opportunities	(2.5)	

Month 6 2022/23: Savings Performance and Identification



	Monthly Performance			Year to Date Performance			Annual 2022-23 & Full Year Effect			
Savings Delivery (£'000)	Mth Plan	Mth Act	Mth Var	YTD Plan	YTD Act	YTD Var	Year Plan	Year Act	Year Var	FYE Plan
Recurrent	760	760	0	814	814	0	1,831	1,805	26	2,409
Amber On Track	0	0	0	0	0	0	38	38	0	150
Green On Track	756	756	0	808	808	0	1,682	1,682	(0)	1,747
Low value	4	4	0	6	6	0	112	86	26	512
Non Recurrent	735	735	0	6,036	6,036	0	12,061	12,061	0	0
Amber Under Delivery	0	0	0	0	0	0	120	120	0	0
Amber On Track	0	0	0	0	0	0	5,265	5,265	0	0
Green On Track	735	735	0	6,036	6,036	0	6,676	6,676	0	0
Grand Total	1,495	1,495	0	6,850	6,850	0	13,893	13,866	26	2,409















Inefficiency activity drivers

Directorate		Demand	Supply			Configuration & Efficiency				Totals
		Ready to leave patients	Agency premium: Medical	Agency premium: Nursing	CHC (£117)	Medically fit patients	Multiple site (A&E & Inpatient)	Multiple site (OP)	Multiple site (Planned Care)	
Unscheduled Care Configuration							16.6	0.8		17.4
Carmarthenshire County		4.0		0.1						4.1
Ceredigion County		2.9								2.9
Pembrokeshire County		3.7		0.2						3.9
Unscheduled Care Bronglais			0.5	0.2		1.8				2.4
Unscheduled Care Glangwili			0.3	2.1		4.3				6.7
Unscheduled Care Prince Philip			0.3	1.2		3.9				5.4
Unscheduled Care Withybush			0.4	1.9		5.6				7.9
Women & Children			0.5	0.2						0.8
Planned Care			1.2	0.8				0.7	1.1	3.7
Mental Health & Learning Disabilities	Carms Pembs Cered		0.3	0.9						1.2
					4.9					4.9
					2.2					2.2
					2.9					2.9
Diagnostics									2.0	2.0
		10.6	3.4	7.5	10.0	15.5	16.6	1.5	3.1	
		10.6			21.0			36.7		68.3

- As the outcome of work surrounding the allocation of resources across based on our population health needs, compared to national benchmarks, inefficiency activity drivers are articulated with financial quantification
- The strategic activity drivers that are having an adverse impact on our financial deficit are split into the three macro elements, Demand, Supply and Configuration & Efficiency
- The organisation has work programmes, led by Executive Directors, to implement improvement activities for each specific micro driver articulated
- Unscheduled Care Configuration broadly relates to the number of hospital sites and front doors we currently manage, which is linked to our long term strategy, so will not have a financial improvement in the short-term

Opportunity programmes

Key	
 = Yes	 = No

Programme	Executive Lead	Operations Lead	Finance Lead	Possible Benefit (£m)	Principle Accepted	Initiation Meeting	Trajectory Agreed	Cash Releasing
Transforming UEC	Andrew Carruthers	Rhian Dawson	Mark Bowling	8.5 *		14/10/22		TBC
Integrated Localities (Bridging)	Jill Paterson	Elaine Lorton	Chris Williams	10.6		13/10/22		TBC
Long Term Care MH&LD	Jill Paterson	Liz Carroll	Leon Popham	10.0		14/10/22		TBC
Nurse Agency	Lisa Gostling	TBC	Andrew Lewis / Jennifer Thomas	7.5		18/10/22		TBC
Medical Agency	Lisa Gostling	TBC	Daniel Binding	3.8		TBC		TBC
Alternative Care Unit	Mandy Rayani	Sharon Daniel	Nick Hogben	7.0 *		14/10/22		TBC
Family Liaison Officers	Mandy Rayani	TBC	Jennifer Thomas	1.0		17/10/22		TBC

* The total possible benefit for combined bed reductions from medically optimised (TUEC) and ready to leave (Alternative Care Unit) patients is £15.5m, with an arbitrary indication split included above.

Executive Summary

	<p>Health Board's revised draft Financial Plan is to deliver a deficit of £62.0m, after savings of £13.9m; this recognises the inadequate level of assurance around the identification of a further £15.5m of savings schemes deliverable within the current financial year against our initial £25.0m deficit Plan. The further deterioration of £21.5m recognises the fruition of the operational variation risk and a transfer into the Core position of COVID-19 responses that were initially planned to be decommissioned, but have been deemed necessary to continue.</p>
Revenue	<ul style="list-style-type: none"> The Month 6 Health Board financial position is an overspend of £6.0m, which is made up of £43.9m operational variance and an original deficit plan of £2.1m; this is after recognising £0.3m of assumed WG transitional funding for COVID-19 and £1.3m for Exceptional Energy costs. £1.5m of savings schemes were delivered in line with identified plans. Of the £3.9m overspend in-month, £1.0m relates to undelivered savings plans against the original target and £2.9m relates to operational pressures. These pressures are mainly being experienced within our Unscheduled Care teams, but also within Medicines Management in relation to Primary Care Prescribing.
Projection	<ul style="list-style-type: none"> The Health Board has received confirmation of WG funding to match the costs of the COVID-19 programmes (Tracing, Testing, Mass Vaccinations and PPE), and has received initial guidance from WG to assume that funding will be provided to offset the transitional costs of COVID-19 of £6.7m and the Exceptional Energy, Health and Social Care Levy and Real Living Wage commissioned services costs of £12.3m. Since our initial plan submission, each Executive Director and their respective leadership teams have been reviewing their operational plans to deliver a step change through a Target Operating Model approach; the basis for our transformation improvement programmes, supported by our Planning Objective structure and governance. Whilst these have yielded benefits, such as our recovery plan to deliver dedicated ring-fenced wards for elective procedures, they are unfortunately not sufficient to improve the financial outlook. The Health Board continues to have to commit expenditure at a consistent rate to maintain services whilst experiencing significant system demand and challenges. Of the identified savings schemes of £13.9m, only a small number are currently assessed as recurrent, with a full year effect of £2.0m. This is contributing to the deterioration in the underlying deficit to £75.0m from the brought forward 2021/22 position of £68.9m, which presents a challenge to be addressed as part of our Target Operating Model.
Savings	<ul style="list-style-type: none"> It is the Board's aspiration that a Target Operating Model can be constructed to focus delivery of services in the most optimum way for our patients and population, and is a critical part of the approach to the medium-term outlook. This will also align with the design assumptions set out in the Health Board's A Healthier Mid and West Wales strategy and Programme Business Case.
Next Steps	<ul style="list-style-type: none"> Following feedback from WG regarding the revised draft Financial Plan, the Board have further challenged teams to urgently identify management actions to reduce the organisation's expenditure trajectory, on an in-year basis as a minimum. We are committed to addressing/mitigating our challenges to get back on track with our financial roadmap; a weekly progress report is being presented to the Executive Team to retain sufficient strategic focus on this key deliverable. Assessment of historic investment decisions for value opportunities, including COVID-19 costs transferred to baseline.

Executive Summary

Summary of key financial targets					
<p>The Health Board's key targets are as follows:</p> <ul style="list-style-type: none"> Revenue: to contain the overspend within the Health Board's planned deficit Savings: to deliver savings plans to enable the revenue budget to be achieved Capital: to contain expenditure within the agreed limit PSPP: to pay 95% of Non-NHS invoices within 30 days of receipt of a valid invoice Cash: While there is no prescribed limit for cash held at the end of the month, WG encourages this to be minimised and a rule of thumb of 5% of monthly expenditure is used. For the Health Board, this is broadly £4.0m. 					
Key target		Annual limit	YTD limit	Actual delivery	Forecast Risk
Revenue	£'m	62.0	28.1	28.9	Low*
Savings	£'m	13.9	6.8	6.8	Low**
Capital	£'m	31.1	8.2	8.2	Low
Non-NHS PSPP	%	95.0	95.0	94.9	Low***
Period end cash	£'m	4.0	4.0	6.4	High****

* The Health Board is forecasting a financial outturn position of £62.0m in line with the re-submitted draft annual plan, which is £37.0m higher than the previous planned deficit of £25.0m. Whilst the delivery risk to the revised deficit of £62.0m is considered to be Low, this is an unacceptable level of deficit and urgent management actions are required to address the underlying position. There is a significant risk that the revised deficit plan may not be accepted by Welsh Government. The re-submitted Plan has been phased in line with the Months 1-3 Actual results and the Month 3 forecast. This decision was taken to prevent reporting to the organisation a YTD or in-month "underspend" against a flat profile of the £62.0m draft deficit as this was considered a misleading message.


** Whilst the delivery of planned savings schemes are on track, the revised annual limit is £15.5m lower than the original plan due to an inadequate level of assurance around the identification of deliverable savings schemes; this lower level of savings has contributed to the increase in the planned deficit of £62.0m. Furthermore, of the identified savings schemes of £13.9m, only a small number are currently assessed as recurrent, with a full year effect of £2.0m. This is contributing to the deterioration in the underlying deficit to £75.0m from the brought forward 2021/22 position of £68.9m, which presents a challenge to be addressed as part of our Target Operating Model.

***The Health Board did not achieve its PSPP target of paying 95% of its non-NHS invoices within 30 days in Quarter 2 (93.6%), which has adversely affected the cumulative position (94.9%). This was caused by delays in authorising invoices by the service; a process has been implemented to assist accounts payable to obtain the authorisation in a timely manner.


**** If WG do not fund the cash consequences of the revenue deficit, there is a significant risk to the period end cash position.

Revenue Summary

YTD variance by Directorate (against Plan)



YTD actual by Directorate (COVID-19 only)




Key drivers of YTD position


- **Savings non delivery £7.8m:** YTD value of savings undelivered by the organisation (against the original Plan requiring delivery of £29.4m);
- **Unscheduled care £9.4m:** Continuation of site pressures where high levels of vacancies and activity are resulting in high variable pay expenditure across all four acute sites;
- **Radiology £1.5m:** Workforce pressures due to vacancies and sickness resulting in high variable pay expenditure across all four acute sites and use of private providers to review reports;
- **Facilities £1.8m:** Overspends are driven in core areas by the increasing cost of utilities and provisions and the loss of revenue in canteens and external vendors. COVID-19 expenditure relates to on-going expenditure in relation to enhanced cleaning standards across all HB estate and remedial works to HB estate;
- **Medicines Management £1.8m:** Baseline price increases and volume growth in Prescribing with significant increases in NCSO and Category M drugs specifically.
- **Public Health £6.3m:** Primarily driven by costs associated with the Health Board's on-going response to COVID-19 in regards to TTP and Mass Vaccinations;
- **WG Programme Funding £(7.5)m:** YTD funding in respect of COVID-19 programme schemes has been included in the position;
- **WG Transitional Funding £(4.8)m** YTD funding has been assumed within the position to match transitional support costs in line with the Health Board's plan to exit, wherever possible, COVID-19 specific activities.

Revenue Summary

YTD variance by Subjective (against Plan)




YTD actual by Subjective (COVID-19 only)





Key drivers of YTD position

- **Savings non delivery £7.8m:** YTD value of savings undelivered by the organisation (against the original Plan requiring delivery of £29.4m);
- **Pay £13.3m:** Continued high levels of variable pay expenditure across various staff groups due to high levels of vacancies across the Health Board and on-going pressures in Unscheduled Care. Continued COVID-19 pay expenditure is primarily supporting the Health Board's response in respect of TTP, Mass Vaccination and enhanced cleaning standards;
- **Drugs £3.4m:** Activity and price growth in Oncology and Scheduled Care following changes in clinical guidelines and a ramp up in activity following COVID-19. There has also been a higher than average increase in drugs as Emergency Departments continue to experience unprecedented demand.
- **Income £(4.6)m:** Primarily driven by the in-month recognition of Value Based Healthcare funding offset by consultancy charges in "Other". British Gas rebates for prior period CHP underperformance. Over achievement in income for the Education Service liaison offset by increased pay costs. Higher than anticipated income received in relation to non contract activity;
- **Premises & Plant £2.5m:** Primarily driven by remedial work to Health Board estate and IT infrastructure costs;
- **WG Programme Funding £(7.5)m:** YTD funding in respect of COVID-19 programme schemes has been included in the position;
- **WG Transitional Funding £(4.8)m** YTD funding has been assumed within the position to match transitional support costs in line with the Health Board's plan to exit, wherever possible, COVID-19 specific activities.

Key Subjective Summary




Key Subjective Summary

<div>CHC</div>  <table><tr><th>Period</th><th>Actual expenditure</th><th>Budgeted expenditure</th></tr><tr><td>P01-22</td><td>4.2</td><td>4.2</td></tr><tr><td>P02-22</td><td>4.3</td><td>4.3</td></tr><tr><td>P03-22</td><td>4.7</td><td>4.7</td></tr><tr><td>P04-22</td><td>4.2</td><td>4.2</td></tr><tr><td>P05-22</td><td>4.1</td><td>4.1</td></tr><tr><td>P06-22</td><td>5.1</td><td>4.5</td></tr><tr><td>P07-22</td><td>4.4</td><td>4.4</td></tr><tr><td>P08-22</td><td>4.3</td><td>4.3</td></tr><tr><td>P09-22</td><td>4.4</td><td>4.4</td></tr><tr><td>P10-22</td><td>4.6</td><td>4.6</td></tr><tr><td>P11-22</td><td>4.1</td><td>4.1</td></tr><tr><td>P12-22</td><td>3.9</td><td>3.9</td></tr><tr><td>P01-23</td><td>4.1</td><td>4.1</td></tr><tr><td>P02-23</td><td>4.3</td><td>4.3</td></tr><tr><td>P03-23</td><td>4.2</td><td>4.2</td></tr><tr><td>P04-23</td><td>4.3</td><td>4.3</td></tr><tr><td>P05-23</td><td>5.5</td><td>4.4</td></tr><tr><td>P06-23</td><td>4.4</td><td>4.4</td></tr><tr><td>P07-23</td><td>4.5</td><td>4.5</td></tr><tr><td>P08-23</td><td>4.4</td><td>4.4</td></tr><tr><td>P09-23</td><td>4.5</td><td>4.5</td></tr><tr><td>P10-23</td><td>4.5</td><td>4.5</td></tr><tr><td>P11-23</td><td>4.1</td><td>4.1</td></tr><tr><td>P12-23</td><td>4.5</td><td>4.5</td></tr></table>	Period	Actual expenditure	Budgeted expenditure	P01-22	4.2	4.2	P02-22	4.3	4.3	P03-22	4.7	4.7	P04-22	4.2	4.2	P05-22	4.1	4.1	P06-22	5.1	4.5	P07-22	4.4	4.4	P08-22	4.3	4.3	P09-22	4.4	4.4	P10-22	4.6	4.6	P11-22	4.1	4.1	P12-22	3.9	3.9	P01-23	4.1	4.1	P02-23	4.3	4.3	P03-23	4.2	4.2	P04-23	4.3	4.3	P05-23	5.5	4.4	P06-23	4.4	4.4	P07-23	4.5	4.5	P08-23	4.4	4.4	P09-23	4.5	4.5	P10-23	4.5	4.5	P11-23	4.1	4.1	P12-23	4.5	4.5	<p>Continuing Health Care expenditure has decreased by £1.0m compared to last month.</p> <p>The primary driver for the reduction is the prior month recognition of the inflationary uplift in Continuing Care packages (£1.2m). This reduction has been offset with a net increase of 18 clients primarily in Adult Palliative Care, Elderly Mentally Ill and Funded Nursing Care.</p>
Period	Actual expenditure	Budgeted expenditure																																																																										
P01-22	4.2	4.2																																																																										
P02-22	4.3	4.3																																																																										
P03-22	4.7	4.7																																																																										
P04-22	4.2	4.2																																																																										
P05-22	4.1	4.1																																																																										
P06-22	5.1	4.5																																																																										
P07-22	4.4	4.4																																																																										
P08-22	4.3	4.3																																																																										
P09-22	4.4	4.4																																																																										
P10-22	4.6	4.6																																																																										
P11-22	4.1	4.1																																																																										
P12-22	3.9	3.9																																																																										
P01-23	4.1	4.1																																																																										
P02-23	4.3	4.3																																																																										
P03-23	4.2	4.2																																																																										
P04-23	4.3	4.3																																																																										
P05-23	5.5	4.4																																																																										
P06-23	4.4	4.4																																																																										
P07-23	4.5	4.5																																																																										
P08-23	4.4	4.4																																																																										
P09-23	4.5	4.5																																																																										
P10-23	4.5	4.5																																																																										
P11-23	4.1	4.1																																																																										
P12-23	4.5	4.5																																																																										
<div>Secondary Care Drugs</div>  <table><tr><th>Period</th><th>Actual expenditure</th><th>Budgeted expenditure</th></tr><tr><td>P01-22</td><td>3.9</td><td>3.6</td></tr><tr><td>P02-22</td><td>4.2</td><td>3.8</td></tr><tr><td>P03-22</td><td>3.7</td><td>3.7</td></tr><tr><td>P04-22</td><td>4.1</td><td>3.7</td></tr><tr><td>P05-22</td><td>3.9</td><td>3.7</td></tr><tr><td>P06-22</td><td>4.3</td><td>3.7</td></tr><tr><td>P07-22</td><td>4.1</td><td>3.9</td></tr><tr><td>P08-22</td><td>4.5</td><td>3.9</td></tr><tr><td>P09-22</td><td>4.4</td><td>3.9</td></tr><tr><td>P10-22</td><td>4.3</td><td>3.9</td></tr><tr><td>P11-22</td><td>4.0</td><td>3.9</td></tr><tr><td>P12-22</td><td>4.5</td><td>3.9</td></tr><tr><td>P01-23</td><td>4.0</td><td>3.9</td></tr><tr><td>P02-23</td><td>4.5</td><td>3.9</td></tr><tr><td>P03-23</td><td>4.2</td><td>3.9</td></tr><tr><td>P04-23</td><td>4.0</td><td>3.8</td></tr><tr><td>P05-23</td><td>4.6</td><td>3.8</td></tr><tr><td>P06-23</td><td>4.9</td><td>4.2</td></tr><tr><td>P07-23</td><td>3.9</td><td>3.8</td></tr><tr><td>P08-23</td><td>3.9</td><td>3.8</td></tr><tr><td>P09-23</td><td>3.9</td><td>3.8</td></tr><tr><td>P10-23</td><td>3.9</td><td>3.8</td></tr><tr><td>P11-23</td><td>3.9</td><td>3.8</td></tr><tr><td>P12-23</td><td>3.9</td><td>3.8</td></tr></table>	Period	Actual expenditure	Budgeted expenditure	P01-22	3.9	3.6	P02-22	4.2	3.8	P03-22	3.7	3.7	P04-22	4.1	3.7	P05-22	3.9	3.7	P06-22	4.3	3.7	P07-22	4.1	3.9	P08-22	4.5	3.9	P09-22	4.4	3.9	P10-22	4.3	3.9	P11-22	4.0	3.9	P12-22	4.5	3.9	P01-23	4.0	3.9	P02-23	4.5	3.9	P03-23	4.2	3.9	P04-23	4.0	3.8	P05-23	4.6	3.8	P06-23	4.9	4.2	P07-23	3.9	3.8	P08-23	3.9	3.8	P09-23	3.9	3.8	P10-23	3.9	3.8	P11-23	3.9	3.8	P12-23	3.9	3.8	<p>Secondary Care Drug expenditure increased by £0.3m in-month compared to last.</p> <p>The main drivers of the increase in drugs was an increase in the issuing of homecare Oncology drugs within the Oncology directorate, an increase in general homecare drugs issued from PPH Pharmacy and a higher than average issue of RSV drug Palivuzumab within Women & Children Services.</p>
Period	Actual expenditure	Budgeted expenditure																																																																										
P01-22	3.9	3.6																																																																										
P02-22	4.2	3.8																																																																										
P03-22	3.7	3.7																																																																										
P04-22	4.1	3.7																																																																										
P05-22	3.9	3.7																																																																										
P06-22	4.3	3.7																																																																										
P07-22	4.1	3.9																																																																										
P08-22	4.5	3.9																																																																										
P09-22	4.4	3.9																																																																										
P10-22	4.3	3.9																																																																										
P11-22	4.0	3.9																																																																										
P12-22	4.5	3.9																																																																										
P01-23	4.0	3.9																																																																										
P02-23	4.5	3.9																																																																										
P03-23	4.2	3.9																																																																										
P04-23	4.0	3.8																																																																										
P05-23	4.6	3.8																																																																										
P06-23	4.9	4.2																																																																										
P07-23	3.9	3.8																																																																										
P08-23	3.9	3.8																																																																										
P09-23	3.9	3.8																																																																										
P10-23	3.9	3.8																																																																										
P11-23	3.9	3.8																																																																										
P12-23	3.9	3.8																																																																										

Key Subjective Summary

<h3>Clinical Supplies and Services</h3> <table><tr><th>Period</th><th>Actual expenditure</th><th>Budgeted expenditure</th></tr><tr><td>P01-22</td><td>2.6</td><td>2.7</td></tr><tr><td>P02-22</td><td>2.5</td><td>2.7</td></tr><tr><td>P03-22</td><td>3.0</td><td>2.9</td></tr><tr><td>P04-22</td><td>3.4</td><td>3.0</td></tr><tr><td>P05-22</td><td>3.4</td><td>2.9</td></tr><tr><td>P06-22</td><td>3.0</td><td>3.5</td></tr><tr><td>P07-22</td><td>2.7</td><td>3.0</td></tr><tr><td>P08-22</td><td>3.1</td><td>2.7</td></tr><tr><td>P09-22</td><td>3.8</td><td>2.9</td></tr><tr><td>P10-22</td><td>5.2</td><td>4.3</td></tr><tr><td>P11-22</td><td>3.5</td><td>3.4</td></tr><tr><td>P12-22</td><td>5.6</td><td>3.9</td></tr><tr><td>P01-23</td><td>3.0</td><td>2.8</td></tr><tr><td>P02-23</td><td>3.2</td><td>3.0</td></tr><tr><td>P03-23</td><td>3.1</td><td>3.0</td></tr><tr><td>P04-23</td><td>3.4</td><td>3.0</td></tr><tr><td>P05-23</td><td>3.1</td><td>2.9</td></tr><tr><td>P06-23</td><td>3.2</td><td>3.0</td></tr><tr><td>P07-23</td><td>2.9</td><td>2.9</td></tr><tr><td>P08-23</td><td>2.9</td><td>2.9</td></tr><tr><td>P09-23</td><td>2.9</td><td>2.9</td></tr><tr><td>P10-23</td><td>2.9</td><td>2.9</td></tr><tr><td>P11-23</td><td>2.9</td><td>2.9</td></tr><tr><td>P12-23</td><td>2.9</td><td>2.9</td></tr></table>	Period	Actual expenditure	Budgeted expenditure	P01-22	2.6	2.7	P02-22	2.5	2.7	P03-22	3.0	2.9	P04-22	3.4	3.0	P05-22	3.4	2.9	P06-22	3.0	3.5	P07-22	2.7	3.0	P08-22	3.1	2.7	P09-22	3.8	2.9	P10-22	5.2	4.3	P11-22	3.5	3.4	P12-22	5.6	3.9	P01-23	3.0	2.8	P02-23	3.2	3.0	P03-23	3.1	3.0	P04-23	3.4	3.0	P05-23	3.1	2.9	P06-23	3.2	3.0	P07-23	2.9	2.9	P08-23	2.9	2.9	P09-23	2.9	2.9	P10-23	2.9	2.9	P11-23	2.9	2.9	P12-23	2.9	2.9	<p>Actual expenditure increased by £0.1m in-month.</p> <p>The increase in expenditure is primarily driven by an increase in elective Gynaecology procedures resulting in an increase in the cost of consumables and the purchase of a number of pace makers within Cardiology.</p>
Period	Actual expenditure	Budgeted expenditure																																																																										
P01-22	2.6	2.7																																																																										
P02-22	2.5	2.7																																																																										
P03-22	3.0	2.9																																																																										
P04-22	3.4	3.0																																																																										
P05-22	3.4	2.9																																																																										
P06-22	3.0	3.5																																																																										
P07-22	2.7	3.0																																																																										
P08-22	3.1	2.7																																																																										
P09-22	3.8	2.9																																																																										
P10-22	5.2	4.3																																																																										
P11-22	3.5	3.4																																																																										
P12-22	5.6	3.9																																																																										
P01-23	3.0	2.8																																																																										
P02-23	3.2	3.0																																																																										
P03-23	3.1	3.0																																																																										
P04-23	3.4	3.0																																																																										
P05-23	3.1	2.9																																																																										
P06-23	3.2	3.0																																																																										
P07-23	2.9	2.9																																																																										
P08-23	2.9	2.9																																																																										
P09-23	2.9	2.9																																																																										
P10-23	2.9	2.9																																																																										
P11-23	2.9	2.9																																																																										
P12-23	2.9	2.9																																																																										
<h3>Primary Care Prescribing</h3> <table><tr><th>Period</th><th>Actual expenditure</th><th>Budgeted expenditure</th></tr><tr><td>P01-22</td><td>6.0</td><td>5.8</td></tr><tr><td>P02-22</td><td>5.8</td><td>5.4</td></tr><tr><td>P03-22</td><td>6.5</td><td>6.2</td></tr><tr><td>P04-22</td><td>6.5</td><td>6.1</td></tr><tr><td>P05-22</td><td>6.0</td><td>5.8</td></tr><tr><td>P06-22</td><td>6.5</td><td>6.3</td></tr><tr><td>P07-22</td><td>6.5</td><td>6.4</td></tr><tr><td>P08-22</td><td>6.4</td><td>6.4</td></tr><tr><td>P09-22</td><td>6.4</td><td>6.4</td></tr><tr><td>P10-22</td><td>5.8</td><td>6.0</td></tr><tr><td>P11-22</td><td>5.6</td><td>5.6</td></tr><tr><td>P12-22</td><td>6.0</td><td>6.2</td></tr><tr><td>P01-23</td><td>6.7</td><td>6.3</td></tr><tr><td>P02-23</td><td>6.2</td><td>6.0</td></tr><tr><td>P03-23</td><td>6.1</td><td>6.0</td></tr><tr><td>P04-23</td><td>6.3</td><td>6.0</td></tr><tr><td>P05-23</td><td>6.8</td><td>6.0</td></tr><tr><td>P06-23</td><td>7.2</td><td>6.1</td></tr><tr><td>P07-23</td><td>6.5</td><td>6.5</td></tr><tr><td>P08-23</td><td>6.5</td><td>6.5</td></tr><tr><td>P09-23</td><td>6.5</td><td>6.5</td></tr><tr><td>P10-23</td><td>6.5</td><td>6.5</td></tr><tr><td>P11-23</td><td>6.5</td><td>6.5</td></tr><tr><td>P12-23</td><td>6.5</td><td>6.5</td></tr></table>	Period	Actual expenditure	Budgeted expenditure	P01-22	6.0	5.8	P02-22	5.8	5.4	P03-22	6.5	6.2	P04-22	6.5	6.1	P05-22	6.0	5.8	P06-22	6.5	6.3	P07-22	6.5	6.4	P08-22	6.4	6.4	P09-22	6.4	6.4	P10-22	5.8	6.0	P11-22	5.6	5.6	P12-22	6.0	6.2	P01-23	6.7	6.3	P02-23	6.2	6.0	P03-23	6.1	6.0	P04-23	6.3	6.0	P05-23	6.8	6.0	P06-23	7.2	6.1	P07-23	6.5	6.5	P08-23	6.5	6.5	P09-23	6.5	6.5	P10-23	6.5	6.5	P11-23	6.5	6.5	P12-23	6.5	6.5	<p>Primary Care Prescribing costs have increased by £0.4m in-month.</p> <p>The primary drivers causing this increase is primarily driven by item growth in the number of baseline items prescribed (the 12-month rolling average has increased from 1.81% to 2.12%). This month has also been impacted by an additional half of a prescribing day in September compared to August. The increase caused by these two factors has been partially offset by a small reduction in the cost per item which is now at £18.69p.</p>
Period	Actual expenditure	Budgeted expenditure																																																																										
P01-22	6.0	5.8																																																																										
P02-22	5.8	5.4																																																																										
P03-22	6.5	6.2																																																																										
P04-22	6.5	6.1																																																																										
P05-22	6.0	5.8																																																																										
P06-22	6.5	6.3																																																																										
P07-22	6.5	6.4																																																																										
P08-22	6.4	6.4																																																																										
P09-22	6.4	6.4																																																																										
P10-22	5.8	6.0																																																																										
P11-22	5.6	5.6																																																																										
P12-22	6.0	6.2																																																																										
P01-23	6.7	6.3																																																																										
P02-23	6.2	6.0																																																																										
P03-23	6.1	6.0																																																																										
P04-23	6.3	6.0																																																																										
P05-23	6.8	6.0																																																																										
P06-23	7.2	6.1																																																																										
P07-23	6.5	6.5																																																																										
P08-23	6.5	6.5																																																																										
P09-23	6.5	6.5																																																																										
P10-23	6.5	6.5																																																																										
P11-23	6.5	6.5																																																																										
P12-23	6.5	6.5																																																																										

Financial Projection



Key Assumptions

- The direct impact of COVID-19, including programme expenditure (in respect of mass vaccination programmes, Testing, Tracing, and PPE) is modelled up to a twelve-month scenario within the current forecast;
- All assumed WG COVID-19 and Exceptional Costs (Energy, Health and Social Care Levy and Real Living Wage commissioned services) funding is based on the current forecast costs on a match-basis.

Assurance

- Executive led Use of Resources Group which scrutinises business cases, opportunities and financial governance.
- Performance to be monitored monthly through robust Directorate Use of Resources meetings.


Concerns

- There has been a net deterioration in the underlying deficit of £68.9m in 2021/22 to the current assessment for 2022/23 of £75.0m based on the re-submission of the Annual Plan, which was not the expected outcome of the revised planning cycle during Quarter 1.

Next Steps

- Following feedback from WG regarding the revised draft Financial Plan, the Board have further challenged teams to urgently identify management actions to reduce the organisation’s expenditure trajectory, on an in-year basis as a minimum.
- Continue to engage with partner organisations to develop plans to address the issues within the Social Care system.
- The anticipated progress against the development of a Target Operating Model (TOM) since the initial submission of the Plan in March has not been delivered and limited in-year benefits have been identified to date. It does, however, remain our aspiration that a TOM can be constructed to focus our delivery of services in the most optimum way for our patients and population, with this forming a critical part of our approach to the medium-term outlook. This will align with the design assumptions set out in our strategy and Programme Business Case. A weekly progress report is being presented to the Executive Team to retain sufficient strategic focus on this key deliverable.
- Assessment of historic investment decisions for value opportunities, including COVID-19 costs transferred to baseline.

Risk-assessed directorate savings profile, delivery and forecast



Assurance

- Of the original £29.4m requirement, £13.9m have been identified as Green schemes, as a minimum on a non-recurrent basis.
- All schemes are now assessed as Green.
- The Plan re-submission is aligned to delivery of the identified savings schemes of £12.4m. Since the Plan, a further £1.5m recurrent Green scheme has been identified.
- In-month delivery of £1.5m, which is in line with the Green savings scheme plans.

Concerns

- Whilst the focus of the Health Board is on identifying and implementing recurrent schemes, the current combination of capacity and COVID-19 pressures being experienced operationally has diverted significant managerial resource. This has meant that, of the original required £29.4m, only £13.9m have been identified, largely on a non-recurrent basis.
- A key factor in worsening the current financial outturn is the recognition of the risk surrounding delivery assurance over the opportunities of £15.5m.

Next Steps

- Having the clarity of the opportunities has enabled the team to buy into the areas that need to be influenced and changed, but we are yet to agree and have sight of detailed plans that illustrate a clear route to delivery through our planning framework.
- This is our key priority and linked to the Target Operating Model. Whilst discussions have been extremely positive in aligning priorities around this approach and the areas of opportunity, we have come to recognise that the impact of delivery for the 2022/23 financial year is only going to be very modest, given the complexities involved within the fragility of the system pressures.
- The Board recognise the need to develop opportunities for change through Use of Resources groups (Directorate level and Executive Level) as a matter of urgency.
- If the re-submitted draft annual plan is approved, the £15.5m savings gap will instead form part of the planned deficit of £62.0m.

This Table is currently showing 0 errors

Line 14 should reflect the corresponding amounts included within the latest MTP/AOP submission to WG
Lines 1 - 14 should not be adjusted after Month 1

	In Year Effect	Non Recurring	Recurring	FYE of Recurring
	£'000	£'000	£'000	£'000
1 Underlying Position bnfed from Previous Year - must agree to M12 MMR (Deficit - Negative Value)	-68,888	0	-68,888	-68,888
2 Planned New Expenditure (Non Covid-19) (Negative Value)	-67,224	-3,762	-59,462	-62,098
3 Planned Expenditure For Covid-19 (Negative Value)	-23,196	-23,196	0	0
4 Planned Welsh Government Funding (Non Covid-19) (Positive Value)	61,746	2,792	53,954	53,954
5 Planned Welsh Government Funding for Covid-19 (Positive Value)	23,196	23,196	0	0
6 Planned Capital Income (Positive Value)	0	0	0	0
7 RRL Profile - planning only (In Year Effect / Column C must be nil)	0	0	0	0
8 Planned (Finalised) Savings Plan	12,366	12,061	305	487
9 Planned (Finalised) Net Income Generation	0	0	0	0
10 Planned Profit / (Loss) on Disposal of Assets	0	0	0	0
11 Planned Release of Uncommitted Contingencies & Reserves (Positive Value)	0	0	0	0
12	0	0	0	0
13 Planning Assumptions still to be finalised at Month 1	0	0	0	0
14 Opening MTP - Annual Operating Plan	42,999	12,061	-74,061	-76,995
15 Reversal of Planning Assumptions still to be finalised at Month 1	0	0	0	0
16 Additional In Year & Movement from Planned Release of Previously Committed Contingencies & Reserves (Positive Value)	0	0	0	0
17 Additional In Year & Movement from Planned Profit / (Loss) on Disposal of Assets	0	0	0	0
18 Other Movement in Month 1 Planned & In Year Net Income Generation	1,000	0	1,000	1,000
19 Overschivement	0	0	0	0
20 Additional In Year Identified Savings - Forecast	489	0	489	489
21 Variance to Planned RRL & Other Income	0	0	0	0
22 Additional In Year & Movement in Planned Welsh Government Funding for Covid-19 (Positive Value - additional)	1,441	1,441	0	0
23 Additional In Year & Movement in Planned Welsh Government Funding (Non Covid) (Positive Value - additional)	0	0	0	0
24 Additional In Year & Movement Expenditure for Covid-19 (Negative Value - additional/Positive Value - reduction)	-1,441	-1,441	0	0
25 In Year Accounting Gains (Positive Value)	0	0	0	0
26 Net In Year Operational Variance to MTP/AOP (material gross amounts to be listed separately)	0	0	0	0
27 Unchecked/Und Care and Facilities and Radiology operational pressures	36	36		
28 Unidentified savings to mitigate operational pressures	-36	-36		
29	-1,489	-1,489		
30	0	0		
31	0	0		
32	0	0		
33	0	0		
34	0	0		
35	0	0		
36 Forecast Outturn (- Deficit / + Surplus)	42,000	10,672	-72,872	-76,816
41 Covid-19 - Forecast Outturn (- Deficit / + Surplus)	0			
42 Operational - Forecast Outturn (- Deficit / + Surplus)	42,000			

	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	YTD	In Year Effect
	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000
1	-5,741	-5,741	-5,741	-5,741	-5,741	-5,741	-5,741	-5,741	-5,741	-5,741	-5,741	-5,741	-34,444	-68,888
2	-4,884	-4,841	-4,260	-5,230	-5,701	-6,038	-6,129	-6,140	-6,123	-6,141	-5,823	-6,233	-30,634	-67,224
3	-2,906	-3,312	-2,239	-1,815	-1,496	-1,853	-1,702	-1,862	-1,896	-1,894	-1,823	-1,638	-13,021	-23,196
4	5,146	5,146	5,146	5,146	5,146	5,146	5,146	5,146	5,146	5,146	5,146	5,146	30,873	61,746
5	2,806	3,312	2,239	1,815	1,496	1,853	1,702	1,862	1,896	1,894	1,823	1,638	13,021	23,196
6	0	0	0	0	0	0	0	0	0	0	0	0	0	0
7	0	0	0	0	0	0	0	0	0	0	0	0	0	0
8	1,013	869	1,652	1,075	743	748	1,319	1,004	789	1,229	803	1,022	6,099	12,366
9	0	0	0	0	0	0	0	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0	0	0	0	0	0	0
14	-4,446	-4,368	-3,264	-4,749	-5,653	-5,885	-5,486	-5,731	-5,929	-5,907	-5,915	-5,897	-28,196	-76,995
15	0	0	0	0	0	0	0	0	0	0	0	0	0	0
16	0	0	0	0	0	0	0	0	0	0	0	0	0	0
17	0	0	0	0	0	0	0	0	0	0	0	0	0	0
18	0	0	0	0	0	500	83	83	83	83	83	83	500	1,000
19	0	0	0	0	0	0	0	0	0	0	0	0	0	0
20	0	0	0	0	0	245	41	41	41	41	41	41	245	489
21	0	0	0	0	0	0	0	0	0	0	0	0	0	0
22	0	0	0	119	-230	23	810	686	-58	-7	2	98	-88	1,441
23	0	0	0	0	0	0	0	0	0	0	0	0	0	0
24	0	0	0	-119	230	-23	-810	-686	58	7	-2	-98	88	-1,441
25	0	0	0	0	0	0	0	0	0	0	0	0	0	0
26	0	0	0	59	-7	-7	-7	-7	-7	-7	-7	-9	45	0
27												36	0	36
28												-36	0	-36
29					-696	-874	6	15	14	13	37	-4	-1,571	-1,489
30													0	0
31													0	0
32													0	0
33													0	0
34													0	0
35													0	0
36	-4,446	-4,268	-3,264	-4,690	-5,236	-5,023	-5,282	-5,690	-5,787	-5,777	-5,762	-5,696	-28,887	-76,816
37	0	0	0	0	0	0	0	0	0	0	0	0	0	0
38	-4,446	-4,268	-3,264	-4,690	-5,236	-5,023	-5,282	-5,690	-5,787	-5,777	-5,762	-5,696	-28,887	-76,816

Table A1 - Underlying Position

Section A - By Spend Area	IMTP	Full Year Effect of Actions			New Year Effect of Undigested Demand (m)	IMTP
	Underlying Position at £'000	Recurring Savings (£'000)	Recurring Allocations (Income) (£'000)	Subtotal £'000	Underlying Position at £'000	Underlying Position at £'000
1 Pay - Administration, Clinical & Board Members	(264)			(264)	(200)	(1,184)
2 Pay - Medical & Dental	(10,496)			(10,496)	4,330	(8,166)
3 Pay - Nursing & Midwifery Registered	(6,562)			(6,562)	(1,103)	(8,465)
4 Pay - Prof Scientific & Technical	(1,814)			(1,814)	500	(814)
5 Pay - Additional Clinical Services	(1,110)			(1,110)	3,655	(1,110)
6 Pay - Allied Health Professionals	1,874			1,874	0	1,874
7 Pay - Healthcare Support Staff	99			99	0	99
8 Pay - Estates & Facilities	25			25	(202)	(202)
9 Pay - Students	0			0	0	0
10 Non Pay - Supplies and services - clinical	(12,140)			(12,140)	(8,297)	(21,700)
11 Non Pay - Supplies and services - general	(1,419)			(1,419)	(2,811)	(9,330)
12 Non Pay - Consumables Services	(812)			(812)	0	(812)
13 Non Pay - Entertainment	(985)			(985)	(100)	(1,485)
14 Non Pay - Transport	(419)			(419)	0	(1,259)
15 Non Pay - Premises	(4,138)			(4,138)	0	(8,059)
16 Non Pay - External Contractors	(1,889)			(1,889)	1,000	(1,889)
17 Health Care Provided by other Orgs - Welsh LHBs	(5,197)			(5,197)	0	(5,197)
18 Health Care Provided by other Orgs - Welsh Trusts	(1,738)			(1,738)	0	(1,738)
19 Health Care Provided by other Orgs - NHS/SC	(12,268)			(12,268)	0	(19,285)
20 Health Care Provided by other Orgs - English	0			0	0	0
21 Health Care Provided by other Orgs - Private / Other	(8,607)			(8,607)	0	(8,607)
22 Total	(88,888)	0	0	(88,888)	(8,128)	(75,016)

Section B - By Directorate	IMTP	Full Year Effect of Actions			New Year Effect of Undigested Demand (m)	IMTP
	Underlying Position at £'000	Recurring Savings (£'000)	Recurring Allocations (Income) (£'000)	Subtotal £'000	Underlying Position at £'000	Underlying Position at £'000
1 Primary Care	(1,165)			(1,165)	0	(1,165)
2 Mental Health	1,810			1,810	0	1,810
3 Community Health Care	(1,264)			(1,264)	0	(1,264)
4 Commissioned Services	(11,817)			(11,817)	1,000	(10,817)
5 Uncontracted Care	(11,869)			(11,869)	7,055	(6,314)
6 Uncontracted Care	(46,000)			(46,000)	(5,121)	(50,997)
7 Children & Young People	(5,365)			(5,365)	0	(5,365)
8 Community Services	122			122	0	122
9 Specialist Services	(8,187)			(8,187)	(6,212)	(11,399)
10 Executive & Corporate Areas	(3,176)			(3,176)	480	(2,897)
11 Support Services (inc. Estates & Facilities)	(1,223)			(1,223)	(212)	(1,435)
12 Total	(88,888)	0	0	(88,888)	(8,128)	(75,016)

Table A2 - Overview Of Key Risks & Opportunities		FORECAST YEAR END	
		£ '000	Likelihood
Opportunities to achieve IMTP/AOP (positive values)			
1	Rad Pipeline schemes (inc AG & IG)		
2	Potential Cost Reduction		
3	Total Opportunities to achieve IMTP/AOP	0	
Risks (negative values)			
4	Under Delivery of Amber Schemes included in Outturn via Tracker		
6	Continuing Healthcare		
6	Prescribing	(2,700)	Medium
7	Pharmacy Contract		
8	WHBSC Performance		
9	Other Contract Performance		
10	GMS Ring Fenced Allocation Underspend Potential Claw back		
11	Dental Ring Fenced Allocation Underspend Potential Claw back		
12			
13	COVID-19 transitional funding not yet confirmed	(6,086)	Low
14	Encapsulated items funding not yet confirmed	(12,252)	Low
15	Rebate for Microsoft SLA via DHCW Saving not repaid directly to Health Boards	(889)	Low
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			
26	Total Risks	(22,167)	
Further Opportunities (positive values)			
27	Target Operating Model		
28	Annual Leave Carryover provision		
29			
30			
31			
32			
33			
34	Total Further Opportunities	0	
35	Current Reported Forecast Outturn	(62,000)	
36	IMTP / AOP Outturn Scenario	(62,000)	
37	Worst Case Outturn Scenario	(84,167)	
38	Best Case Outturn Scenario	(62,000)	

Table B - Monthly Positions

A. Monthly Summarised Statement of Comprehensive Net Expenditure / Statement of Comprehensive Net Income															Total YTD		Forecast year-end position	
	1	2	3	4	5	6	7	8	9	10	11	12						
	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar						
	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	£'000	
1 Revenue Reserves (Government Grant Income (Health Board only))	Actual/Foast	85,768	84,841	84,074	83,629	83,034	82,538	81,873	81,782	81,304	80,351	84,485	87,420	916,944	1,007,599			
2 Capital Donations (Government Grant Income (Health Board only))	Actual/Foast	0	0	0	100	0	0	0	0	0	0	0	0	0	100			
3 Welsh NHS Local Health Boards & Trusts Income	Actual/Foast	2,476	2,820	2,668	2,300	3,125	3,444	2,730	2,734	2,720	2,696	2,706	2,706	18,796	33,189			
4 WMSBC Income	Actual/Foast	202	220	319	319	186	283	230	230	230	230	230	230	2,377	278			
5 Welsh Government Income (Non RRS)	Actual/Foast	453	(147)	195	320	184	194	194	194	194	194	194	194	1,163	2,327			
6 Other Income	Actual/Foast	732	2,831	2,385	2,385	2,262	3,031	2,382	2,413	2,327	2,389	2,389	2,389	14,751	28,373			
7 Income Total	Actual/Foast	89,641	89,487	89,378	89,642	89,699	100,778	89,512	91,375	91,644	92,619	90,392	92,699	649,699	1,164,430			
8 Primary Care (including GP practices) (including non resource limited expenditure)	Actual/Foast	13,712	10,289	9,854	10,429	10,166	11,089	10,417	10,311	9,824	9,824	9,824	10,000	64,128	127,729			
9 Primary Care - Drugs & Appliances	Actual/Foast	6,744	6,744	6,744	6,744	6,744	7,728	7,236	6,997	7,086	6,821	6,285	6,285	42,161	83,629			
10 Provided Services - Pay	Actual/Foast	42,871	42,135	42,807	42,801	42,439	43,901	44,809	44,870	44,894	44,724	46,181	46,181	288,944	569,730			
11 Provided Services - Non Pay (including drugs & depreciation)	Actual/Foast	8,474	8,393	7,964	7,806	8,793	8,974	9,067	9,067	9,063	9,066	10,121	9,641	49,867	98,149			
12 Secondary Care - Drugs	Actual/Foast	4,804	4,804	4,804	4,804	4,804	4,804	4,804	4,804	4,804	4,804	4,804	4,804	29,467	58,934			
13 Healthcare Services Provided by Other NHS Bodies	Actual/Foast	14,138	14,233	14,233	14,064	14,717	14,889	14,482	14,482	14,482	14,482	14,482	14,482	87,401	174,803			
14 Non Healthcare Services Provided by Other NHS Bodies	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
15 Continuing Care and Funded Nursing Care	Actual/Foast	4,163	4,327	4,136	4,227	4,403	4,518	4,687	4,688	4,731	4,731	4,731	4,731	28,001	56,376			
16 Other Private & Voluntary Sector	Actual/Foast	79	543	584	612	344	360	176	176	176	176	176	176	1,134	2,209			
17 Joint Financing and Other	Actual/Foast	108	85	102	106	87	106	87	110	110	110	110	110	609	1,209			
18 Losses, Special Payments and Irrecoverable Debts	Actual/Foast	120	127	(10)	130	103	120	143	143	143	143	143	143	881	1,439			
19 Exceptional Income / Costs - (Trust Only)	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
20 Total Interest Receivable - (Trust Only)	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
21 Total Interest Payable - (Trust Only)	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
22 RRS Depreciation/Amortisation Depreciation/Impairments	Actual/Foast	2,033	2,038	2,038	1,882	2,009	2,009	2,043	2,043	1,904	2,571	2,038	2,358	11,999	24,547			
23 AME Donated Depreciation/Impairments	Actual/Foast	62	62	62	63	63	63	61	61	61	60	60	60	375	730			
24 Uncommitted Reserves & Contingencies	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
25 Profit/Loss Disposal of Assets	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
26 Cost - Total	Actual/Foast	94,487	92,728	92,382	92,152	91,556	100,268	98,234	98,072	97,641	96,188	98,234	98,664	674,486	1,194,538			
27 Net surplus/ (deficit)	Actual/Foast	(1,446)	(1,506)	(1,506)	(1,506)	(1,506)	(1,506)	(1,506)	(1,506)	(1,506)	(1,506)	(1,506)	(1,506)	(1,506)	(1,506)			
B. Cost Total by Directorate																		
	1	2	3	4	5	6	7	8	9	10	11	12	Total YTD	Forecast year-end position				
	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	£'000	£'000				
28 Primary Care	Actual/Foast	10,055	9,733	9,584	9,654	9,897	10,598	10,519	10,482	10,653	10,798	10,455	69,918	134,454				
29 Mental Health	Actual/Foast	5,039	5,182	4,941	5,212	5,055	5,912	5,059	5,114	5,099	5,180	5,180	31,522	62,188				
30 Continuing Healthcare	Actual/Foast	4,207	4,207	4,207	4,207	4,207	4,208	4,207	4,207	4,207	4,207	4,207	25,719	51,438				
31 Commissioned Services	Actual/Foast	13,323	13,417	14,405	13,501	13,603	13,924	13,898	13,898	13,898	13,898	13,898	82,434	164,869				
32 Specialist Care	Actual/Foast	9,403	9,368	9,405	10,073	9,825	11,018	10,691	10,182	10,182	10,182	10,182	60,992	121,984				
33 Uncommitted Care	Actual/Foast	12,353	12,711	12,638	12,883	12,497	15,684	13,813	13,813	13,813	13,813	13,813	79,774	159,548				
34 Children & Women's	Actual/Foast	3,477	3,464	3,630	3,668	3,633	4,538	3,738	3,804	3,773	3,789	3,789	22,867	45,734				
35 Community Services	Actual/Foast	5,999	6,168	5,950	6,109	6,498	6,923	6,920	6,920	6,920	6,920	6,920	42,222	84,444				
36 Specialist Services	Actual/Foast	14,880	14,977	14,884	15,224	15,823	17,599	15,890	15,890	15,890	15,890	15,890	99,955	199,910				
37 Executive - Corporate Areas	Actual/Foast	7,724	6,944	7,033	6,849	7,041	6,989	7,412	8,182	8,492	8,026	8,026	44,981	89,962				
38 Support Services (inc. Estates & Facilities)	Actual/Foast	4,880	4,735	4,718	4,738	4,553	6,314	4,461	4,582	4,582	4,582	4,582	29,544	59,088				
39 Reserve	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
40 Cost - Total (Excluding DEL & AME Non-Cash Charges)	Actual/Foast	91,262	91,646	91,062	91,197	91,843	106,268	96,006	96,066	96,071	96,071	96,071	606,114	1,141,246				
C. Assessment of Financial Forecast Positions																		
Year-to-date YTD																		
£'000																		
28. Actual YTD surplus/ (deficit)	(18,897)																	
29. Actual YTD surplus/ (deficit) last month	(22,494)																	
30. Current month actual surplus/ (deficit)	(6,025)																	
31. Average monthly surplus/ (deficit) YTD	(4,815)																	
32. YTD remaining months	(4,815)																	
Trend																		
Year-to-date YTD																		
£'000																		
33. Extrapolated Scenario	(18,897)																	
34. Year to Date Trend Scenario	(17,714)																	
D. DEL/AME Depreciation & Impairments																		
	1	2	3	4	5	6	7	8	9	10	11	12	Total YTD	Forecast year-end position				
	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	£'000	£'000				
DEL	Actual/Foast	1,328	1,328	884	1,098	1,098	1,130	1,130	611	1,881	1,141	1,355	8,328	13,814				
35 Baseline Provider Depreciation	Actual/Foast	1,328	1,328	884	1,098	1,098	1,130	1,130	611	1,881	1,141	1,355	8,328	13,814				
36 Strategic Depreciation	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0				
37 Accelerated Depreciation	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0				
38 Impairments	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0				
39 IFRS 16 Leases	Actual/Foast	207	204	212	39	165	168	148	148	148	148	148	258	903	1,987			
40 Total	Actual/Foast	2,633	2,628	2,056	1,652	2,666	2,609	2,645	2,645	1,984	2,971	2,952	2,588	11,994	24,547			
AME	Actual/Foast	62	62	62	61	63	62	60	60	61	59	59	55	375	730			
41 Donated Asset Depreciation	Actual/Foast	62	62	62	61	63	62	60	60	61	59	59	55	375	730			
42 Impairments (including Reserves)	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
43 IFRS 16 Leases	Actual/Foast	62	62	62	61	63	62	60	60	61	59	59	55	375	730			
44 Total	Actual/Foast	62	62	62	61	63	62	60	60	61	59	59	55	375	730			
D. Accountancy Gains																		
	1	2	3	4	5	6	7	8	9	10	11	12	Total YTD	Forecast year-end position				
	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	£'000	£'000				
45 Accountancy Gains	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
E. Uncommitted Reserves & Contingencies																		
	1	2	3	4	5	6	7	8	9	10	11	12	Total YTD	Forecast year-end position				
	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	£'000	£'000				
46 Uncommitted Reserves & Contingencies	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
F. List of all Committed Reserves & Contingencies (inc. above in Section A. Please specify Row number in description)																		
	1	2	3	4	5	6	7	8	9	10	11	12	Total YTD	Forecast year-end position				
	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	£'000	£'000				
46	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
47	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
48	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
49	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
50	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
51	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
52	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
53	Forecast Only	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
74 Total	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
Phases																		
	1	2	3	4	5	6	7	8	9	10	11	12	Total YTD	Forecast year-end position				
	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	£'000	£'000				
45	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
46	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
47	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
48	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
49	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
50	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
51	Actual/Foast	0	0	0	0	0	0	0	0	0	0	0						

Table B2 - Pay Expenditure Analysis

A - Pay Expenditure													
REF	TYPE	1	2	3	4	5	6	7	8	9	10	11	12
		Apr £'000	May £'000	Jun £'000	Jul £'000	Aug £'000	Sep £'000	Oct £'000	Nov £'000	Dec £'000	Jan £'000	Feb £'000	Mar £'000
1	Administrative, Clinical & Board Members	6,415	6,432	6,444	6,384	6,454	6,448	6,740	6,762	6,753	6,749	6,754	6,758
2	Medical & Dental	9,365	9,369	9,367	9,364	10,017	11,427	9,739	9,379	9,916	9,864	9,687	9,844
3	Nursing & Midwifery Registered	13,881	13,881	14,135	14,134	13,807	17,261	14,820	14,820	14,336	14,855	14,847	14,847
4	Prof Scientific & Technical	1,306	1,375	1,359	1,330	1,383	1,750	1,534	1,515	1,515	1,503	1,573	1,463
5	Additional Clinical Services	6,123	6,025	6,068	6,153	6,022	6,374	6,421	6,038	6,452	6,413	6,309	6,439
6	Allied Health Professionals	3,043	3,041	3,124	3,091	3,034	3,324	3,055	3,043	3,037	3,050	3,045	3,045
7	Healthcare Scientists	879	863	867	862	868	1,100	1,004	1,004	1,000	1,000	1,000	1,000
8	Estates & Ancillary	2,509	2,432	2,359	2,475	2,308	2,375	2,375	2,375	2,368	2,368	2,368	2,368
9	Students	3	3	3	3	2	0	0	0	0	0	0	0
10	TOTAL PAY EXPENDITURE	43,822	43,223	43,884	43,997	43,813	50,391	46,172	46,134	46,337	45,985	45,972	46,444
Analysis of Pay Expenditure													
11	LARS Provided Services - Pay	42,671	42,155	42,637	42,981	42,430	53,901	44,909	44,935	44,694	44,724	44,708	45,181
12	Other Services (incl. Primary Care) - Pay	152	1,068	1,037	1,146	1,375	1,490	1,263	1,204	1,263	1,262	1,264	1,263
13	Total - Pay	43,823	43,223	43,884	43,997	43,814	50,391	46,172	46,134	46,287	45,986	45,972	46,444
B - Agency / Locum (premium) Expenditure													
- Analysed by Type of Staff													
REF	TYPE	1	2	3	4	5	6	7	8	9	10	11	12
		Apr £'000	May £'000	Jun £'000	Jul £'000	Aug £'000	Sep £'000	Oct £'000	Nov £'000	Dec £'000	Jan £'000	Feb £'000	Mar £'000
1	Administrative, Clinical & Board Members	27	28	30	9	5	121	32	32	32	32	32	32
2	Medical & Dental	409	646	627	459	463	511	623	653	653	653	623	653
3	Nursing & Midwifery Registered	1,871	2,109	2,258	2,284	2,123	2,632	2,319	2,319	2,319	2,319	2,319	2,319
4	Prof Scientific & Technical	2	2	2	2	2	2	2	2	2	2	2	2
5	Additional Clinical Services	2	2	1	18	11	8	8	8	8	8	8	8
6	Allied Health Professionals	125	131	116	47	106	112	111	111	111	111	111	111
7	Healthcare Scientists	48	35	55	55	76	45	26	26	26	26	26	26
8	Estates & Ancillary	16	6	21	16	8	8	12	12	12	12	12	12
9	Students	0	0	0	0	0	0	0	0	0	0	0	0
10	TOTAL AGENCY/LOCUM (PREMIUM) EXPENDITURE	2,372	2,863	2,989	2,792	2,812	3,406	3,062	3,062	3,062	3,062	3,062	3,062
11	Agency/Locum (premium) % of pay	5.4%	6.6%	6.8%	6.2%	6.4%	6.8%	6.6%	6.6%	6.6%	6.6%	6.6%	6.6%
C - Agency / Locum (premium) Expenditure													
- Analysed by Reason for Using Agency/Locum (premium)													
REF	REASON	1	2	3	4	5	6	7	8	9	10	11	12
		Apr £'000	May £'000	Jun £'000	Jul £'000	Aug £'000	Sep £'000	Oct £'000	Nov £'000	Dec £'000	Jan £'000	Feb £'000	Mar £'000
1	Vacancy	1,859	2,357	2,328	2,429	2,415	3,158	2,689	2,689	2,689	2,689	2,689	2,689
2	Maternity/Paternity/Adoption Leave	0	0	0	0	0	0	0	0	0	0	0	0
3	Special Leave (Paid) - inc. compassionate leave, interview	2	3	3	3	3	3	4	3	3	3	3	3
4	Special Leave (Unpaid)	0	0	0	0	0	0	0	0	0	0	0	0
5	Study Leave/Examinations	0	0	0	0	0	0	0	0	0	0	0	0
6	Additional Activity (Other Pressures/Site Pressures)	189	238	239	262	268	288	244	244	244	244	244	244
7	Annual Leave	0	0	0	0	0	0	0	0	0	0	0	0
8	Sickness	86	72	72	75	75	86	83	83	83	83	83	83
9	Reinstatement Duties	0	0	0	0	0	0	0	0	0	0	0	0
10	Jury Service	0	0	0	0	0	0	0	0	0	0	0	0
11	WOL	0	0	0	0	0	0	0	0	0	0	0	0
12	Exclusion (Suspension)	0	0	0	0	0	0	0	0	0	0	0	0
13	COVID-19	296	327	342	33	86	40	44	44	44	44	44	44
14	TOTAL AGENCY/LOCUM (PREMIUM) EXPENDITURE	2,372	2,863	2,989	2,792	2,812	3,406	3,062	3,062	3,062	3,062	3,062	3,062

Table B3 - COVID-19 Analysis

A - Additional Expenditure														Total YTD		Forecast year-end	
1														£'000		£'000	
2														£'000		£'000	
3														£'000		£'000	
4														£'000		£'000	
5														£'000		£'000	
6														£'000		£'000	
7														£'000		£'000	
8														£'000		£'000	
9														£'000		£'000	
10														£'000		£'000	
11														£'000		£'000	
12														£'000		£'000	
13														£'000		£'000	
14														£'000		£'000	
15														£'000		£'000	
16														£'000		£'000	
17														£'000		£'000	
18														£'000		£'000	
19														£'000		£'000	
20														£'000		£'000	
21														£'000		£'000	
22														£'000		£'000	
23														£'000		£'000	
24														£'000		£'000	
25														£'000		£'000	
26														£'000		£'000	
27														£'000		£'000	
28														£'000		£'000	
29														£'000		£'000	
30														£'000		£'000	
31														£'000		£'000	
32														£'000		£'000	
33														£'000		£'000	
34														£'000		£'000	
35														£'000		£'000	
36														£'000		£'000	
37														£'000		£'000	
38														£'000		£'000	
39														£'000		£'000	
40														£'000		£'000	
41														£'000		£'000	
42														£'000		£'000	
43														£'000		£'000	
44														£'000		£'000	
45														£'000		£'000	
46														£'000		£'000	
47														£'000		£'000	
48														£'000		£'000	
49														£'000		£'000	
50														£'000		£'000	
51														£'000		£'000	
52														£'000		£'000	
53														£'000		£'000	
54														£'000		£'000	
55														£'000		£'000	
56														£'000		£'000	
57														£'000		£'000	
58														£'000		£'000	
59														£'000		£'000	
60														£'000		£'000	
61														£'000		£'000	
62														£'000		£'000	
63														£'000		£'000	
64														£'000		£'000	
65														£'000		£'000	
66														£'000		£'000	

Table C - Identified Expenditure Savings Schemes (Excludes Income Generation & Accountancy Gains)

		1	2	3	4	5	6	7	8	9	10	11	12	Total YTD	Full-year forecast	FTD as %age of FY FTD variance as %age of FYTD Budget/Past	Assessment		Full In-Year forecast		Full-Year Effect of Resource Savings £'000
		Apr £'000	May £'000	Jun £'000	Jul £'000	Aug £'000	Sep £'000	Oct £'000	Nov £'000	Dec £'000	Jan £'000	Feb £'000	Mar £'000				Green £'000	Amber £'000	non recording £'000	recording £'000	
1	Budget/Past	0	0	0	0	0	0	0	200	0	0	0	0	0	200		200	0			
2	Actual/Past	0	0	0	0	0	0	0	200	0	0	0	0	0	200	0.00%	200	0	200	0	0
3	Variance	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	0			0
4	Budget/Past	100	100	100	100	100	100	100	100	100	100	100	100	600	1,200		1,200	0			
5	Actual/Past	100	100	100	100	100	100	100	100	100	100	100	100	600	1,200	50.00%	1,200	0	1,200	0	0
6	Variance	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	0			0
7	Budget/Past	49	48	53	51	49	53	48	51	53	148	148	153	300	900		900	0			
8	Actual/Past	49	48	53	51	49	53	48	51	53	148	148	153	300	900	33.33%	900	0	900	0	0
9	Variance	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	0			0
10	Budget/Past	43	43	50	46	46	50	43	46	49	130	130	131	489	1,469		1,469	0			
11	Actual/Past	43	43	50	46	46	50	43	46	49	130	130	131	489	1,469	48.51%	1,469	0	1,469	0	864
12	Variance	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	0			0
13	Budget/Past	821	879	599	599	528	528	557	557	558	558	557	558	3,711	7,058		7,058	0			
14	Actual/Past	821	879	599	558	528	528	557	557	558	558	557	558	3,711	7,058	52.58%	7,058	0	7,058	51	102
15	Variance	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	0			0
16	Budget/Past	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	0			
17	Actual/Past	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	0	0	0	0
18	Variance	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	0			0
19	Budget/Past	1,013	889	1,052	1,075	743	743	748	1,319	1,024	789	1,229	903	1,022	6,099		12,368	0			
20	Actual/Past	1,013	889	1,052	1,075	743	743	748	1,319	1,024	789	1,229	903	1,022	6,099	48.55%	12,368	0	12,368	794	955
21	Variance	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	0			0
22	Variance in month	0.00%	0.00%	0.00%	0.00%	0.00%	52.71%	3.12%	4.08%	5.16%	3.31%	4.51%	3.99%								
23	in month achievement against	7.88%	6.79%	12.05%	6.37%	5.78%	7.72%	10.58%	8.13%	6.48%	9.88%	7.34%	8.27%								

Table D - Income/Expenditure Assumptions						
Annual Forecast						
LHB/Trust		Contracted Income	Non Contracted Income	Total Income	Contracted Expenditure	Non Contracted Expenditure
		£'000	£'000	£'000	£'000	£'000
1	Swansea Bay University	3,869	529	4,398	36,630	3,295
2	Aneurin Bevan University	366	627	993	300	16
3	Bethel Cadwaladr University	4,991	179	5,170	238	4
4	Cardiff & Vale University	345	279	624	6,097	934
5	Coventry & Warwickshire University	493	72	565	483	297
6	Hywel Dda University			0		
7	Phylis	7,810	1,047	8,857	198	70
8	Public Health Wales	2,738	442	3,180	1,708	563
9	Valindia		5,136	5,136	15,205	7,431
10	NHSUW			0		
11	DHCUW	453		453	3,761	
12	Wales Ambulance Services		87	87	2,230	
13	WHSUW	1,735		1,735	88,068	(2,080)
14	EASUW			0	31,620	
15	HEUW		8,564	8,564	3	
16	NHS Wales Executive			0		
17	Total	22,968	16,972	39,940	182,379	12,666

Table E - Resource Limits		STATUS OF ISSUED RESOURCE LIMIT ITEMS				Total Revenue or Recurring (R) Resource Limit	Total Revenue or Non Recurring (NR)	Total Revenue Drawing Limit	Total Capital Resource Limit	Total Capital Drawing Limit
1. BASE ALLOCATION		HCHS	Pharmacy	Dental	GMS	£'000	£'000	£'000	£'000	£'000
1. LATEST ALLOCATION LETTER/SCHEDULE REF:		49	1	2	5	1	2	3	4	5
2. Total Confirmed Funding		864,371	21,889	19,824	75,068	981,132		958,575	31,051	31,051
2. ANTICIPATED ALLOCATIONS										
3. DEL. Non Cash Depreciation - Baseline Surplus / Shortfall						0	NR			
4. DEL. Non Cash Depreciation - Buildings						0	NR			
5. DEL. Non Cash Depreciation - Accelerated						0				
6. DEL. Non Cash Depreciation - Impairment						0				
7. DEL. Non Cash Depreciation - IFRS 16 Leases		1,867				1,867	NR			
8. AMR. Non Cash Depreciation - IFRS 16 Leases (Peppercorn)						0				
9. AMR. Non Cash Depreciation - Donated Assets		735				735	NR			
10. AMR. Non Cash Depreciation - Impairment						0				
11. AMR. Non Cash Depreciation - Impairment Reversals						0				
12. Removal of Donated Assets / Government Grant Receipts		(100)				(100)	NR			
13. Total COVID-19 (see below analysis)			0	0	0			0		
14. Removal of IFRS 16 Leases (Revenue)		(1,912)				(1,912)	NR			
15. Energy (Price Increases)		7,452				7,452	NR	7,452		
16. Employment NI Increases (1.25%)		1,800				1,800	R	1,800		
17. Real Living Wage		3,040				3,040	R	3,040		
18. Children & Young Peoples Mental Health & Emotional Wellbeing		200				200	R	200		
19. EASC/OMAST Improvements in MH emergency calls		42				42	R	42		
20. Pharmacy Delivering a Healthcare Wales - Digital Signposting Tool		20				20	R	20		
21. B1-2 Pay Award		199				199	R	199		
22. WYSSC - Callers		86				86	R	86		
23. Urgent and Emergency Care		2,800				2,800	R	2,800		
24. Six Goals for Urgent and Emergency Care Programme, Six Goals Improvement Trauma/Trauma T&T		160				160	NR	160		
25. HHHW (Healthier Weight, Healthier Wales, Obesity)		374				374	NR	374		
26. Welsh Risk Pool		(2,722)				(2,722)	NR	(2,722)		
27. Overtime during Annual Leave (MF-12 2021/22)		150				150	NR	150		
28. Value Based Health Care		0				0	NR	0		
29. L&HC, Alnal Ffiliatlon Re-design regional response		217				217	NR	217		
30. Overtime during Annual leave (MF-4 2022/23)		888				888	R	888		
31. MHLD Alternatives to admission		384				384	NR	384		
32. MHLD Primary care liaison and tier 0/1		125				125	NR	125		
33. Teledermatology pathway funding		38				38	NR	38		
34. Centre for Sustainable Healthcare Sustainability Fellowship within Value-based Healthcare		57				57	NR	57		
35. Real Living Wage (Bands 1 & 2, 2022/23)		843				843	NR	843		
36. Memory Assessment Services West Wales RPH 2021/22		(196)				(196)	NR	(196)		
37. Q14 General Surgery Clinical Lead X Ems		4				4	NR	4		
38. FY2023 Inflationary pay increase		21,537				21,537	R	21,537		
39						0		0		
40. NHS pay award, additional funding for community pharmacy			376			376	R	0		
41										
42										
43										
44										
45										
46										
47										
48										
49										
50										
51										
52										
53										
54										
55										
56 Total Anticipated Funding		66,092	376	0	0	66,468		65,382	0	0
3. TOTAL RESOURCES & BUDGET RECONCILIATION										
57. Confirmed Resources Per 1 above		864,371	21,889	19,824	75,068	981,132		958,575	31,051	31,051
58. Anticipated Resources Per 2 above		66,092	376	0	0	66,468		65,382	0	0
59. Total Resources		930,463	22,265	19,824	75,068	1,037,600		1,013,857	31,051	31,051
ANALYSIS OF WG FUNDING FOR COVID-19 INCLUDED ABOVE		Allocated Total	Anticipated HCHS	Anticipated Pharmacy	Anticipated Dental	Anticipated GMS	Total RRL			
60. Testing (inc Community Testing)		404	805				1,210			
61. Tracing		1,328	1,462				2,790			
62. Mass COVID-19 Vaccination		1,943	6,795				8,738			
63. PPE		549	1,559				2,108			
64. Extended Flu		943					943			
65. Cleaning Standards			1,284				1,284			
66. Long Covid			578				578			
67. A2. Increased bed capacity specifically related to COVID-19			1,594				1,594			
68. A3. Other Capacity & facilities costs			905				905			
69. B1. Prescribing changes directly related to COVID symptoms			776				776			
70. C1. Increased workforce costs as a direct result of the COVID response and IP&C guidance			1,036				1,036			
71. D1. Discharge Support			299				299			
72. D6. Support for National Programmes through Shared Service							0			
73. D5. Other Services that support the ongoing COVID response			462	366			888			
74. E1. Primary Care Contractor (excluding drugs) - Costs as a result of lost GDS income			1,089				1,089			
75										
76										
77										
78										
79										
80										
81										
82										
83										
84										
85										
86										
87										
88										
89										
90 Total Funding		6,763	17,884	0	0	0	24,637			

Table F - Statement of Financial Position For Monthly Period		Opening Balance	Closing Balance	Least Closing Balance
To complete from Month 1		Beginning of	End of	End of
		Apr 22	Jul 22	Mar 23
		£'000	£'000	£'000
Non-Current Assets				
1	Property, plant and equipment	311,562	335,146	334,659
2	Intangible assets	2,784	2,407	2,407
3	Trade and other receivables	168,964	67,933	68,904
4	Other financial assets	0	0	0
5	Non-Current Assets sub-total	483,248	405,486	405,967
Current Assets				
6	Inventory	10,399	10,648	15,399
7	Trade and other receivables	53,285	53,442	53,285
8	Other financial assets	0	0	0
9	Cash and cash equivalents	1,960	8,387	862,400
10	Non-current assets classified as held for sale	0	0	0
11	Current Assets sub-total	65,249	72,471	1,684
12	TOTAL ASSETS	488,499	477,957	467,651
Current Liabilities				
13	Trade and other payables	175,380	164,181	168,642
14	Borrowings (Trust Only)	0	0	0
15	Other financial liabilities	0	0	0
16	Provisions	22,400	26,391	26,391
17	Current Liabilities sub-total	197,780	176,572	176,833
18	NET ASSETS LESS CURRENT LIABILITIES	270,719	301,385	231,618
Non-Current Liabilities				
19	Trade and other payables	0	11,736	11,736
20	Borrowings (Trust Only)	0	0	0
21	Other financial liabilities	0	0	0
22	Provisions	70,059	60,420	60,420
23	Non-Current Liabilities sub-total	70,059	72,156	72,156
24	TOTAL ASSETS EMPLOYED	200,650	233,227	199,460
FINANCED BY:				
Taxpayers' Equity				
25	General Fund	168,450	201,043	127,278
26	Resignation Reserve	32,200	32,184	32,184
27	FSC (Trust only)	0	0	0
28	Retained earnings (Trust Only)	0	0	0
29	Other reserves	0	0	0
30	Total Taxpayers' Equity	200,650	233,227	199,460
EXPLANATION OF ALL PROVISIONS		Opening Balance	Closing Balance	Closing Balance
		Beginning of	End of	End of
		Apr 22	May 22	Mar 23
31	EXPLANATION OF ALL PROVISIONS	83,819	78,618	78,618
32	Credit impairment	939	723	723
33	Redress	4,610	4,569	4,569
34	Personal Injury	1,641	2,277	1,277
35	Defence fees	923	923	923
36	2019-20 Scheme Pays - Reimbursement	11	16	16
37	Pensions	706	686	686
38	Other			
39				
40	Total Provisions	92,459	86,811	86,811
ANALYSIS OF WELSH NHS RECEIVABLES (current month)			£'000	
41	Welsh NHS Receivables Aged 0 - 10 weeks		901	
42	Welsh NHS Receivables Aged 11 - 16 weeks		0	
43	Welsh NHS Receivables Aged 17 weeks and over		0	
44	ANALYSIS OF TRADE & OTHER PAYABLES (opening, current & closing)	£'000	£'000	£'000
44	Capital	20,504	19,123	13,504
45	Revenue	124,876	136,796	147,876
ANALYSIS OF CASH (opening, current & closing)		£'000	£'000	£'000
46	Capital	490	2,861	500
47	Revenue	1,078	3,820	862,400

Table G - Monthly Cashflow Forecast

	April £'000	May £'000	June £'000	July £'000	Aug £'000	Sept £'000	Oct £'000	Nov £'000	Dec £'000	Jan £'000	Feb £'000	Mar £'000	Total £,000
RECEIPTS													
1 WG Revenue Funding - Cash Limit (excluding NCL) - LHB & SHA only	93,127	91,127	91,127	94,127	83,127	105,398	84,187	90,320	94,193	76,693	86,693	23,838	1,013,907
2 WG Revenue Funding - Non Cash Limited (NCL) - LHB & SHA only	(127)	(127)	(127)	(127)	(127)	(368)	(187)	(522)	(193)	(193)	(193)	(193)	(2,314)
3 WG Revenue Funding - Other (e.g. invoices)	466	121	0	242	2,756	278	500	500	500	500	500	500	4,891
4 WG Capital Funding - Cash Limit - LHB & SHA only	14,300	1,300	2,500	2,700	0	3,500	200	1,600	1,163	1,163	1,163	1,162	31,051
5 Income from other Welsh NHS Organisations	6,226	3,722	6,802	2,705	5,181	4,510	2,500	2,000	2,800	2,500	2,500	2,500	44,146
6 Short Term Loans - Trust only	0	0	0	0	0	0	0	0	0	0	0	0	0
7 PDC - Trust only	0	0	0	0	0	0	0	0	0	0	0	0	0
8 Interest Receivable - Trust only	0	0	0	0	0	0	0	0	0	0	0	0	0
9 Sale of Assets	0	0	0	68	0	0	0	0	0	0	0	0	122
10 Other - (Specify in narrative)	3,645	2,063	2,963	1,528	2,356	6,677	3,681	4,229	5,979	3,879	4,329	4,329	42,297
11 TOTAL RECEIPTS	117,847	98,206	103,285	101,242	93,293	116,656	95,930	96,879	102,392	84,242	94,642	32,136	1,156,160
PAYMENTS													
12 Primary Care Services - General Medical Services	5,029	5,169	6,513	5,029	4,890	5,434	4,693	4,693	4,693	4,693	4,693	4,693	60,822
13 Primary Care Services - Pharmacy Services	3,332	0	2,018	1,938	1,926	3,200	0	1,900	3,000	0	1,900	3,000	20,919
14 Primary Care Services - Prescribed Drugs & Appliances	11,460	0	5,805	6,074	5,785	12,255	417	6,500	13,000	0	6,500	12,500	80,296
15 Primary Care Services - General Dental Services	1,471	1,416	1,403	1,400	1,594	1,364	1,366	1,400	1,400	1,400	1,400	1,400	16,858
16 Non Cash Limited Payments	(117)	(221)	(225)	(193)	(244)	(222)	(193)	(222)	(193)	(193)	(193)	(193)	(2,314)
17 Salaries and Wages	41,285	42,438	41,464	42,053	41,255	45,746	46,899	44,315	44,441	44,315	44,315	44,441	523,031
18 Non Pay Expenditure	42,221	43,245	44,532	42,717	37,853	41,531	41,698	37,320	34,282	33,500	34,428	26,530	462,332
19 Short Term Loan Repayment - Trust only	0	0	0	0	0	0	0	0	0	0	0	0	0
20 PDC Repayment - Trust only	0	0	0	0	0	0	0	0	0	0	0	0	0
21 Capital Payment	13,480	1,044	1,118	2,350	584	3,723	2,272	1,900	1,163	1,163	1,163	1,263	31,173
22 Other Items (Specify in narrative)	2,286	871	76	6	13	73	483	550	700	500	500	600	6,658
23 TOTAL PAYMENTS	121,048	84,716	102,708	100,636	93,166	113,215	97,686	97,862	102,466	84,465	94,397	97,363	1,195,715
24 Net cash inflow/outflow	(3,801)	(5,490)	(556)	(507)	(107)	(3,457)	(1,656)	(587)	(541)	(2,223)	(255)	(60,227)	
25 Balance b/f	1,674	(1,816)	2,230	2,837	2,944	6,381	2,726	3,313	3,219	2,992	3,227	(60,000)	
26 Balance c/f	(1,816)	1,674	2,230	2,837	2,944	6,381	2,726	3,313	3,219	2,992	3,227	(60,000)	

Table H - PSPP													
30 DAY COMPLIANCE													
PROMPT PAYMENT OF INVOICE PERFORMANCE	Target %	ACTUAL Q1		ACTUAL Q2		ACTUAL Q3		ACTUAL Q4		YEAR TO DATE		FORECAST YEAR END	
		Actual %	Variance %	Actual %	Variance %	Actual %	Variance %	Actual %	Variance %	Actual %	Variance %	Forecast %	Variance %
1 % of NHS Invoices Paid Within 30 Days - By Value	95.0%	99.9%	4.9%	99.3%	4.3%		-95.0%		-95.0%	99.6%	4.6%	95.0%	0.0%
2 % of NHS Invoices Paid Within 30 Days - By Number	95.0%	95.7%	-0.7%	94.5%	-0.5%		-95.0%		-95.0%	95.1%	-0.1%	95.0%	0.0%
3 % of Non NHS Invoices Paid Within 30 Days - By Value	95.0%	97.0%	2.0%	96.5%	1.5%		-95.0%		-95.0%	97.4%	2.4%	95.0%	0.0%
4 % of Non NHS Invoices Paid Within 30 Days - By Number	95.0%	96.3%	1.3%	93.6%	-1.4%		-95.0%		-95.0%	94.9%	-0.1%	95.0%	0.0%
10 DAY COMPLIANCE													
PROMPT PAYMENT OF INVOICE PERFORMANCE		ACTUAL Q1		ACTUAL Q2		ACTUAL Q3		ACTUAL Q4		YEAR TO DATE		FORECAST YEAR END	
		Actual %		Actual %		Actual %		Actual %		Actual %		Actual %	
5 % of NHS Invoices Paid Within 10 Days - By Value		58.1%		51.3%						54.7%		75.0%	
6 % of NHS Invoices Paid Within 10 Days - By Number		47.1%		29.4%						39.3%		50.0%	
7 % of Non NHS Invoices Paid Within 10 Days - By Value		64.4%		69.1%						66.7%		50.0%	
8 % of Non NHS Invoices Paid Within 10 Days - By Number		30.6%		48.4%						39.5%		50.0%	

Table I - Capital Resource / Expenditure Limit Management

		£'000		31.06.21	
		Approved CRL / CEL issued at :		5.10.22	
Ref:	Performance against CRL / CEL	Plan £'000	Actual £'000	Variance £'000	
	Gross expenditure (accrued, to include capitalised finance leases) All Wales Capital Programme: Schemes:				
1	Gangneil - Fire Enforcement works - Phase 1	2,049	2,049	0	
2	Withybush - Fire Enforcement works - Phase 1	2,742	2,742	0	
3	Neonolles - Phase II - main	332	332	0	
4	U29 - Multi-site projects	0	0	0	
5	FFH Demonstration	608	608	0	
6	Fire Enforcement Works - Withybush Hospital- Decant Ward Fees	124	124	0	
7	Withybush - Fire Enforcement works fees - Phase 2	324	324	0	
8	National Programme - Decarbonisation	27	27	0	
9	National Programme - Fire	109	109	0	
10	National Programme - Mental Health	44	44	0	
11	National Programme - Imaging	99	99	0	
12	National Programme - Imaging - CT Scanner PPH	297	297	0	
13	National Programme - Imaging - CT Scanner BGR	67	67	0	
14	National Programme - Imaging - DR Rooms	201	201	0	
15	National Programme - Imaging - Fluoroscopy Rooms	83	83	0	
16	Cross Hands Primary - Care scheme	63	63	0	
17	EDV funding 21/22	0	0	0	
18	Business Continuity Programme - Feep	0	0	0	
19	Gangneil - Fire Enforcement works - Phase 1	0	0	0	
20	DPIF - Digital Medicines Transformation Pre-implementation team	0	0	0	
21	Additional Imaging	9	9	0	
22				0	
23				0	
24				0	
41	Sub Total	7,168	7,168	0	
42	Discretionary:			0	
43	IT	142	142	0	
44	Equipment	411	411	0	
45	Statutory Compliance	66	66	0	
46	Utilities	183	183	0	
47	Other	199	199	0	
48	Sub Total	999	999	0	
	Other Schemes:				
49	Donated additions	100	100	0	
50	Equipment disposals	0	0	0	
51				0	
52				0	
53				0	
54	Sub Total	100	100	0	
69	Total Expenditure	8,267	8,267	0	
70	Less:				
	Capital grants:				
71				0	
72				0	
73				0	
74				0	
75				0	
76	Sub Total	0	0	0	
	Donations:				
77	Donations	100	100	0	
78	Sub Total	100	100	0	
	Asset Disposals:				
79	Equipment	70	70	0	
80				0	
81				0	
82				0	
83				0	
84	Sub Total	70	70	0	
91	Technical Adjustments			0	
92	CHARGE AGAINST CRL / CEL	8,087	8,087	0	
93	PERFORMANCE AGAINST CRL / CEL (Under/Over		(2,164)		

Forecast		
Plan £'000	Forecast £'000	Variance £'000
6,027	6,027	0
6,959	6,959	0
808	1,067	261
373	322	(51)
1,699	1,699	0
188	188	0
935	935	0
595	595	0
125	125	0
440	440	0
314	295	(19)
1,219	1,219	0
941	941	0
1,888	1,888	0
1,670	1,670	0
0	75	75
0	0	0
150	150	0
1,089	1,089	0
8	8	0
215	215	0
		0
		0
		0
25,761	25,989	228
199	199	0
2,398	2,398	0
437	437	0
1,590	1,590	0
605	438	(167)
5,290	5,062	(228)
100	100	0
123	123	0
		0
		0
		0
223	223	0
31,274	31,274	(0)
		0
		0
		0
		0
0	0	0
100	100	0
100	100	0
123	123	0
		0
		0
123	123	0
		0
		0
		0
31,051	31,051	(0)
		0

Table J - In Year Capital Scheme Profiles

Ref.	All Wales Capital Programme: Schemes:	Project Manager	In Year Forecast		Capital Expenditure Monthly Profile												YTD £'000	Total £'000	Risk Level
			Min. £'000	Max. £'000	April £'000	May £'000	Jun £'000	Jul £'000	Aug £'000	Sep £'000	Oct £'000	Nov £'000	Dec £'000	Jan £'000	Feb £'000	Mar £'000			
1	Gargelli - Fire Enforcement works - Phase 1	RE	5,026	5,026	115	280	294	550	487	343	579	579	579	578	579	1,085	2,549	6,927	Low
2	Withybush - Fire Enforcement works - Phase 1	RE	6,960	6,960	328	451	1	746	847	369	675	675	675	675	675	643	2,742	6,960	Low
3	Neonatal - Phase II - main	KJ	1,567	1,567	138	94	28	40	27	46	60	37	30	49	117	422	332	1,567	Low
4	IGS - Multi-site projects	RE	322	322	0	0	0	0	0	0	0	0	65	65	65	65	0	322	Low
5	PPH Demountable	KJ	1,899	1,899	390	(15)	144	56	36	17	0	0	407	400	464	0	628	1,899	Low
6	Fire Enforcement Works - Withybush Hospital- Decant Ward Fees	RE	188	188	3	65	2	48	(27)	32	32	32	0	0	0	0	134	188	Low
7	Withybush - Fire Enforcement works less - Phase 2	RE	935	935	0	6	3	123	189	157	239	199	45	5	5	0	324	935	Low
8	National Programme - Decarbonisation	RE	654	654	0	3	43	(10)	14	138	151	323	0	0	0	18	27	654	Low
9	National Programme - Fire	RE	126	126	5	0	(8)	33	1	75	15	0	0	0	0	0	199	126	Low
10	National Programme - Mental Health	LC	148	420	0	0	0	48	(5)	(4)	64	83	72	0	22	135	44	420	Medium
11	National Programme - Imaging	GR	296	296	16	24	7	62	8	2	50	17	0	0	90	0	99	296	Low
12	National Programme - Imaging - CT Scanner PPH	GR	1,217	1,217	0	2	0	6	30	258	420	300	200	0	0	0	297	1,217	Low
13	National Programme - Imaging - CT Scanner BHM	GR	942	942	0	4	1	1	81	(10)	0	80	380	380	95	0	87	942	Low
14	National Programme - Imaging - Dxt Rooms	GR	1,869	1,869	0	1	30	33	35	102	470	632	316	215	35	0	291	1,869	Low
15	National Programme - Imaging - Fluoroscopy Rooms	GR	1,570	1,570	0	0	0	0	31	23	0	328	338	328	328	205	83	1,570	Low
16	Cross Hands Primary Care scheme	RD	75	75	0	14	30	6	6	6	7	5	0	0	0	0	63	75	Low
17	EOY funding 2102	GR	0	0	0	0	0	0	401	(651)	0	0	0	0	0	0	0	0	Low
18	Business Continuity Programme - Fees	RE	150	150	0	0	0	0	0	0	0	0	0	0	75	75	0	150	Low
19	Gargelli - Fire Enforcement works - Phase 1	RE	1,089	1,089	0	0	0	0	0	0	0	200	200	200	200	289	0	1,089	Low
20	DPVF - Digital Medicines Transformation Pre-implementation team	AJ	8	8	0	0	0	0	0	0	0	0	0	0	0	0	8	8	Low
21	Additional Imaging	GR	215	215	0	0	0	0	0	9	0	0	0	160	56	0	9	215	Low
22																	0	0	
23																	0	0	
24																	0	0	
25																	0	0	
26																	0	0	
34	Sub Total		25,716	25,987	983	929	575	1,602	1,997	1,072	2,667	3,424	3,734	3,055	2,806	3,145	7,158	25,989	
Discretionary:																			
35	IT	AT	200	200	0	34	16	22	(8)	69	10	21	0	10	17	0	141	199	Low
36	Equipment	GR	2,399	2,399	0	0	0	0	0	411	15	57	518	699	877	120	411	2,399	Low
37	Statutory Compliance	RE	437	437	0	2	5	2	10	42	66	57	20	22	163	44	46	437	Low
38	Estates	RE	1,590	1,590	1	3	7	14	84	73	154	144	240	310	405	155	183	1,590	Low
39	Other	Various	438	438	2	30	39	15	45	40	42	42	42	42	72	0	197	433	Low
40	Sub Total		5,063	5,063	3	78	67	63	165	636	287	321	820	1,083	1,234	319	999	5,062	
Other Schemes (Including IFRS 16 Leases):																			
41	Donated additions	Various	100	100				100									100	100	Low
42	Equipment disposals	Various	123	123											123		0	123	Low
43																	0	0	
44																	0	0	
45																	0	0	
46																	0	0	
47																	0	0	
48																	0	0	
49																	0	0	
51	Sub Total		223	223	0	0	0	100	0	0	0	0	0	0	123	0	100	223	
Total Capital Expenditure																			
62			31,002	31,274	986	1,004	642	1,765	2,161	1,708	2,954	3,745	4,654	4,138	4,163	3,464	8,256	31,274	

Table K - Capital Disposals									
A: In Year Disposal of Assets									
	Description	Date of Ministerial Approval to Dispose (Land & Buildings only) MM/YY (text format, e.g. Apr 23)	Date of Ministerial Approval to Retain Proceeds > £0.5m MM/YY (text format, e.g. Apr 23)	Date of Disposal MM/YY (text format, e.g. Feb 23)	NBV £'000	Sales Receipts £'000	Cost of Disposals £'000	Gain/ (Loss) £'000	Comments
1	Equipment disposals	03	03	Jul 22	123	123	0	0	
2								0	
3								0	
4								0	
5								0	
6								0	
7								0	
8								0	
9								0	
10								0	
11								0	
12								0	
13								0	
14								0	
15								0	
16								0	
17								0	
18								0	
19								0	
	Total for in-year				123	123	0	0	

Table M - Debtors Schedule									
11 weeks before end of Sep 22 = 15 July 2022									
17 weeks before end of Sep 22 = 03 June 2022									
Debtor	Inv #	Inv Date	Orig Inv £	Outstand. Inv £	Valid Entry	>11 weeks old <17 weeks	Over 17 weeks	Arbitration Due Date	Comments
			0.00	0.00		0.00	0.00		
Invoices paid since the end of the month						0.00	0.00		
Total outstanding as per M0 submission date						0.00	0.00		

Table N - General Medical Services
Operating Expenditure - ring fenced GMS budget
Required from Month 6

SUMMARY OF GENERAL MEDICAL SERVICES FINANCIAL POSITION						Year to Date
	LINE NO.	WG Allocation £000's	Current Plan £000's	Forecast Outturn £000's	Variance £000's	£000's
Global Sum	1					16,437
Revised support payment	2					163
Total Global Sum and MPFG	3	41,830	36,362	36,075	(317)	16,938
GPAT Acquisition Payments	4					1,603
GPAT Achievement Payments	5					763
GPAT Access Achievement Payments	6					963
Total GPATs	7	5,038	5,723	5,778	9	3,363
GPAT Enhanced Services (Ex equal data in Section A (ii) Line 31)	8			2,207	2,209	189
National Enhanced Services (Ex equal data in Section A (ii) Line 41)	9			188	385	188
Local Enhanced Services (Ex equal data in Section A (ii) Line 95)	10			1,229	2,381	1,129
Total Enhanced Services (Ex equal data in Section A Line 95)	11	0,726	4,444	5,413	369	2,188
GPATs Administered (Ex equal data in Section B Line 100)	12		2,280	2,484	2,509	4,481
GPATs Administered (Ex equal data in Section C Line 100)	13		5,761	4,275	3,381	1,581
GPATs Administered (Ex equal data in Section D Line 100)	14					0
GPATs Administered (Ex equal data in Section E Line 100)	15		4,825	2,788	2,081	2,713
GPATs Administered (Ex equal data in Section F Line 100)	16		5,658	5,873	4,722	2,363
GPATs Administered (Ex equal data in Section G Line 100)	17		15,588	15,588	15,581	15,581
SUPPLEMENTARY INFORMATION						
Directed Enhanced Services Section A (i)						
Learning Disabilities	18					£000's
Childhood Immunisation Scheme	19		509	430	(79)	215
Minor Injuries	20					0
Influenza & Pneumococcal Immunisation Scheme	21		1,048	1,048	0	14
Services for Vulnerable Patients	22					0
Minor Surgery Fees	23		109	253	144	127
GPATs Administered Section A (ii)						
GPATs Administered (Ex equal data in Section B Line 100)	24		401	412	0	208
GPATs Administered (Ex equal data in Section C Line 100)	25		401	412	0	17
GPATs Administered (Ex equal data in Section D Line 100)	26		301	389	88	100
GPATs Administered (Ex equal data in Section E Line 100)	27		41	41	0	2
GPATs Administered (Ex equal data in Section F Line 100)	28		15	15	0	0
GPATs Administered (Ex equal data in Section G Line 100)	29					0
GPATs Administered (Ex equal data in Section H Line 100)	30		82	105	23	83
TOTAL Directed Enhanced Services (must equal line 8)	31		2,887	2,799	(88)	887
National Enhanced Services Section A (iii)						
GPATs Administered	32					£000's
GPATs Administered (Ex equal data in Section B Line 100)	33		125	282	157	145
GPATs Administered (Ex equal data in Section C Line 100)	34					0
GPATs Administered (Ex equal data in Section D Line 100)	35		35	77	42	35
GPATs Administered (Ex equal data in Section E Line 100)	36					0
GPATs Administered (Ex equal data in Section F Line 100)	37					0
GPATs Administered (Ex equal data in Section G Line 100)	38					0
GPATs Administered (Ex equal data in Section H Line 100)	39					0
GPATs Administered (Ex equal data in Section I Line 100)	40					0
TOTAL National Enhanced Services (must equal line 9)	41		188	385	212	188
Local Enhanced Services Section A (iv)						
GPATs Administered	42					£000's
GPATs Administered (Ex equal data in Section B Line 100)	43		4	223	219	112
GPATs Administered (Ex equal data in Section C Line 100)	44					0
GPATs Administered (Ex equal data in Section D Line 100)	45					0
GPATs Administered (Ex equal data in Section E Line 100)	46					0
GPATs Administered (Ex equal data in Section F Line 100)	47					0
GPATs Administered (Ex equal data in Section G Line 100)	48					0
GPATs Administered (Ex equal data in Section H Line 100)	49		77	105	28	75
GPATs Administered (Ex equal data in Section I Line 100)	50					0
GPATs Administered (Ex equal data in Section J Line 100)	51					0
GPATs Administered (Ex equal data in Section K Line 100)	52		105	114	9	87
GPATs Administered (Ex equal data in Section L Line 100)	53		23	283	260	144
GPATs Administered (Ex equal data in Section M Line 100)	54		12	12	0	12
GPATs Administered (Ex equal data in Section N Line 100)	55		30	125	95	53
GPATs Administered (Ex equal data in Section O Line 100)	56					0
GPATs Administered (Ex equal data in Section P Line 100)	57					0
GPATs Administered (Ex equal data in Section Q Line 100)	58		2	2	0	1
GPATs Administered (Ex equal data in Section R Line 100)	59		125	125	0	61
GPATs Administered (Ex equal data in Section S Line 100)	60					0
GPATs Administered (Ex equal data in Section T Line 100)	61					0
GPATs Administered (Ex equal data in Section U Line 100)	62					0
GPATs Administered (Ex equal data in Section V Line 100)	63					0
GPATs Administered (Ex equal data in Section W Line 100)	64					0
GPATs Administered (Ex equal data in Section X Line 100)	65					0
GPATs Administered (Ex equal data in Section Y Line 100)	66					0
GPATs Administered (Ex equal data in Section Z Line 100)	67					0
GPATs Administered (Ex equal data in Section AA Line 100)	68					0
GPATs Administered (Ex equal data in Section AB Line 100)	69		18	12	(6)	10
GPATs Administered (Ex equal data in Section AC Line 100)	70		125	75	(50)	35
GPATs Administered (Ex equal data in Section AD Line 100)	71					0
GPATs Administered (Ex equal data in Section AE Line 100)	72					0
GPATs Administered (Ex equal data in Section AF Line 100)	73					0
GPATs Administered (Ex equal data in Section AG Line 100)	74					0
GPATs Administered (Ex equal data in Section AH Line 100)	75					0
GPATs Administered (Ex equal data in Section AI Line 100)	76					0
GPATs Administered (Ex equal data in Section AJ Line 100)	77					0
GPATs Administered (Ex equal data in Section AK Line 100)	78					0
GPATs Administered (Ex equal data in Section AL Line 100)	79					0
GPATs Administered (Ex equal data in Section AM Line 100)	80					0
GPATs Administered (Ex equal data in Section AN Line 100)	81					0
GPATs Administered (Ex equal data in Section AO Line 100)	82					0
GPATs Administered (Ex equal data in Section AP Line 100)	83					0
GPATs Administered (Ex equal data in Section AQ Line 100)	84					0
GPATs Administered (Ex equal data in Section AR Line 100)	85					0
GPATs Administered (Ex equal data in Section AS Line 100)	86		1,200	792	(408)	328
GPATs Administered (Ex equal data in Section AT Line 100)	87		35	215	180	100
GPATs Administered (Ex equal data in Section AU Line 100)	88		31	31	0	17
GPATs Administered (Ex equal data in Section AV Line 100)	89					0
GPATs Administered (Ex equal data in Section AW Line 100)	90					0
GPATs Administered (Ex equal data in Section AX Line 100)	91					0
GPATs Administered (Ex equal data in Section AY Line 100)	92					0
GPATs Administered (Ex equal data in Section AZ Line 100)	93					0
TOTAL Local Enhanced Services (must equal line 10)	94		1,628	2,348	610	1,122
TOTAL Enhanced Services (must equal line 11)	95		4,444	5,413	369	2,188

GENERAL MEDICAL SERVICES
Operating Expenditure

Required from Month 6

LHB Administered		Section B	LINE NO.	WG Allocation £000's	Current Plan £000's	Forecast Outturn £000's	Variance £000's	Year to Date £000's
General								
Doctors Retention Scheme Payments			87					300
Locum Allowances - costs of adoption, paternity & maternity			88					28
Locum Allowances - Cover for Sick Leave			89					13
Locum Allowances - Cover for Suspended Doctors			90					
Prolonged Sick Leave			101					
Recruitment and Retention (including Golden Hello)			102					
Appraisal - Appraisal Costs			103					
Primary Care Development Scheme			104					
Partnership Payments - GP partners			105					351
Partnership Payments - Non GP Partners			106					
Supply of supplies & materials			107					3,002
Other (please provide detail below, this should reconcile to line 128)			108					
TOTAL LHB Administered (must equal line 12)			109	2,204	8,404	8,909	(493)	4,455
Analysis of Other Payments (line 108)			LINE NO.	£000's	£000's	£000's	£000's	£000's
Additional Managed Practice costs (costs in excess of Global SumMPD)			110					
CME checks			111					
CME course payments			112					
LHB Locally group costs			113					
Managing Practice costs (LHB employed staff working in GP practices to improve GP services)			114					3,350
Primary Care Initiatives			115					
Salaries of GP costs			116					
Stationery & Distribution			117					
Training			118					
Transportation fees			119					
Practice equipment payments to GP practices			120					104
Packaging and Storage			121					8
Postage			122					40
GP Staff Payments			123					43
			124					102
			125					
Other			126					
TOTAL of Other Payments (must equal line 108)			127					3,662
Premises		Section C	LINE NO.	£000's	£000's	£000's	£000's	£000's
National Beds			128					101
Actual Beds Health Centres			129					
Actual Beds Clinics			130					821
Cost Rent			131					
General Waste Trade Refuse			132					102
Water, Water, sewerage etc			133					203
Health centre Charges			134					
Improvement Grants			135					
All other Premises (please detail below which should reconcile to line 146)			136					
TOTAL Premises (must equal line 13)			137					
Analysis of Other Premises (line 137)			LINE NO.	£000's	4,762	4,915	3,961	5,961
DV Fees			138					
			139					
			140					
			141					
			142					
			143					
			144					
TOTAL of Other Premises (must equal line 137)			145					0
Water/sewerage fees			147					
Enhanced Services included above but in dispute with LMC (TOTAL)			148					
Enhanced Services included above but not yet formally agreed LMC								

GENERAL MEDICAL SERVICES
Dispensing

Dispensing Data		LINE NO.	WG Allocation £000's	Current Plan £000's	Forecast Outturn £000's	Variance £000's	Year to Date £000's
Cost of Drugs and Appliances, after discounts and plus container allowance (and plus VAT where applicable)							
Dispensing Section		149					1,265
Prescription Medical Practitioners - Personal Administration		150					584
Dispensing Section Locality Payment		151					
Professional Fees and on-cost							
Dispensing Section		152					442
Prescribing Medical Practitioners - Personal Administration		153					50
TOTAL DISPENSING DATA (must equal line 16)		154	5,658	5,933	4,722	5,191	2,361

Table O - General Dental Services
Operating Expenditure from the revenue allocation for the dental contract

Required from: Month 6						Year to Date	
SUMMARY OF DENTAL SERVICES FINANCIAL POSITION							
Expenditure Activities included in a DDS contract and / or FDS agreement	LINE NO	WG Allocation	Current Plan	Forecast Outturn	Variance		
		£000's	£000's	£000's	£000's		
Gross Contract Value - Personal Dental Services	1		17,833	17,843	(10)	8,767	
Gross Contract Value - General Dental Services	2				0		
Emergency Dental Services (in Out of hours)	3				0		
Additional Access	4		64	70	(6)	30	
Business Rates	5				(1)		
Domiliary Services	6		40	100	(60)	53	
Maternity/Childcare etc.	7				0		
Sanitation services including GA	8				0		
Insurance payments	9				0		
Employer's Superannuation	10		658	1,309	(651)	408	
Other staff	11				0		
OTHER							
PLEASE DETAIL	12		3,013	3,009	4	1,708	
BELOW	13	19,824	23,826	23,108	694	11,031	
TOTAL DENTAL SERVICES EXPENDITURE							
agreement. This includes payments made under other arrangements e.g. GA under an SLA and DDS, plus	LINE NO		£000's	£000's	£000's		
Emergency Dental Services (in Out of hours)	14						
Additional Access	15			480		240	
Sanitation services including GA	16						
Continuing professional development	17						
Consequential Health / Health &	18						
Green Am Byts - Oral Health in care homes	19						
Refund of patient charges	20			412		214	
Design & Sign	21			1,684		867	
Other Community Dental Services	22			40		202	
Dental Education Training/Continual Training	23			14		6	
DBS/CPS checks	24			751		373	
Health Board staff costs associated with the delivery / monitoring of the dental contract	25						
Oral Surgery	26						
Orthodontics	27						
Special care dentistry e.g. WHC/2016/002	28						
Oral Health Promotion/Education	29						
Insurance expenditure in dental practices	30						
Alford Anywhere	31			585		68	
CCF	32						
Travel Income	33			(100)		(180)	
Dental Practitioners	34						
Other Income	35						
Dental Staff Payment	36						
	37						
	38						
	39						
	40						
	41						
	42			1,988		1,768	
TOTAL OTHER (must equal line 13)	43						
TOTAL DENTAL SERVICES INCOME (Enter as a negative value)	44		(2,870)	(1,326)	748	(840)	